{"gene":"IRF5","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":2005,"finding":"IRF5 physically interacts with MyD88 and TRAF6, and TLR activation via the TLR-MyD88 pathway results in nuclear translocation of IRF5 to activate transcription of proinflammatory cytokine genes (IL-6, IL-12, TNF-α); Irf5−/− mice show severely impaired cytokine induction by TLR ligands and resistance to lethal endotoxin shock.","method":"Irf5−/− mouse genetics, co-immunoprecipitation (IRF5 with MyD88/TRAF6), nuclear translocation assay, cytokine measurement in vivo and in vitro","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction evidence, in vivo KO phenotype with defined molecular mechanism, replicated in multiple TLR contexts","pmids":["15665823"],"is_preprint":false},{"year":2002,"finding":"IRF5 contains a constitutive-activation domain (aa 410–489), an autoinhibitory domain (aa 490–539), and two functional nuclear localization signals (N- and C-terminal). Serine residues 477 and 480 are critical phosphorylation sites required for IRF5 transactivation in virus-infected cells; Ser→Ala mutations dramatically reduced phosphorylation and transcriptional activity.","method":"Deletion mutagenesis, site-directed mutagenesis, transient transfection reporter assays, phosphorylation analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of specific residues with direct functional readout, multiple domain-mapping experiments in one study","pmids":["12138184"],"is_preprint":false},{"year":2004,"finding":"IRF5 subcellular localization is controlled by a functional CRM1-dependent nuclear export signal (NES); mutation of two leucine residues in the NES results in constitutive nuclear accumulation. IRF5 is phosphorylated by IKKε and TBK1 in co-transfected cells, but this phosphorylation does not lead to nuclear localization or activation of IRF5.","method":"CRM1 inhibitor (leptomycin B), NES mutagenesis, subcellular fractionation/imaging, co-transfection kinase assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with direct localization readout, pharmacological validation, clear negative result for TBK1/IKKε-mediated activation","pmids":["15556946"],"is_preprint":false},{"year":2009,"finding":"IKKα phosphorylates IRF5 and induces IRF5 dimerization; however, this phosphorylation exerts an inhibitory effect on IRF5 transcriptional activity by blocking K63-linked ubiquitination that is required for IRF5 activity. Alkaline phosphatase interacts with IRF5 and causes its dephosphorylation, suggesting an autoregulatory loop.","method":"Co-immunoprecipitation, in vitro kinase assay, ubiquitination assay, reporter gene assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single lab, co-IP and in vitro kinase assay with functional readout, but limited independent replication","pmids":["19786094"],"is_preprint":false},{"year":2014,"finding":"IKKβ phosphorylates IRF5 at serine 445 (S446 in human IRF5 isoform 1) in response to TLR and RIG-I-like receptor stimulation. A point mutation of Ser445 abolished IRF5 activation and cytokine production. IKKβ depletion or pharmacological inhibition prevented IRF5 phosphorylation.","method":"In vitro kinase assay with recombinant IKKβ, mass spectrometry phosphosite identification, phospho-specific antibody, site-directed mutagenesis, siRNA knockdown, pharmacological inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with recombinant kinase, MS-identified phosphosite, mutagenesis confirmation, validated with multiple orthogonal methods","pmids":["25326420"],"is_preprint":false},{"year":2014,"finding":"IKKβ phosphorylates IRF5 at Ser462 in myeloid cells, inducing IRF5 dimerization and nuclear translocation. The IRF5[Ser462Ala] mutant failed to translocate to the nucleus after TLR7 stimulation. TAK1 acts as an upstream activator of IKKβ in this pathway. IKKβ-mediated IRF5 phosphorylation is required for IFNβ production in plasmacytoid dendritic cells.","method":"In vitro kinase assay (IKKβ phosphorylating IRF5 at Ser462), site-directed mutagenesis, siRNA knockdown of IKKβ and TAK1, pharmacological inhibition, nuclear translocation imaging","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, mutagenesis, siRNA and pharmacological inhibition, concordant with PMID 25326420","pmids":["25326418"],"is_preprint":false},{"year":2011,"finding":"IRF5 directly activates transcription of IL-12p40, IL-12p35, and IL-23p19 genes and represses the IL-10 gene in M1 macrophages. IRF5 expression is reversibly induced by inflammatory stimuli and its high expression is characteristic of M1 macrophages, contributing to macrophage polarization plasticity.","method":"Chromatin immunoprecipitation (ChIP) at target gene promoters, IRF5 overexpression, gene expression profiling, macrophage polarization assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct promoter binding plus functional gene expression data, replicated by multiple labs","pmids":["21240265"],"is_preprint":false},{"year":2014,"finding":"IRF5 recruits to regulatory elements of inflammatory genes in LPS-stimulated macrophages using a composite PU.1:ISRE motif in vivo. IRF5 physically interacts with RelA (NF-κB p65), and this IRF5:RelA interaction is required for regulation of a subset of key inflammatory genes. The RelA:IRF5 interaction domain was mapped.","method":"Genome-wide ChIP-seq, protein:DNA microarrays (in vitro DNA binding), co-immunoprecipitation, gene expression profiling in IRF5- and RelA-deficient macrophages","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq, in vitro DNA binding, reciprocal co-IP, KO macrophage transcriptomics, multiple orthogonal methods","pmids":["25159141"],"is_preprint":false},{"year":2002,"finding":"IRF5 is a direct transcriptional target of p53: a p53-binding site in exon 2 of the IRF5 gene binds p53 protein (EMSA), drives p53-dependent reporter activity, and IRF5 mRNA is induced by DNA damage (γ-irradiation, UV, adriamycin) in a p53-dependent manner.","method":"Differential display, EMSA, heterologous reporter assay, DNA damage induction in p53+/+ vs p53−/− cells","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EMSA with direct binding plus functional reporter assay, multiple DNA damage stimuli tested","pmids":["11973653"],"is_preprint":false},{"year":2010,"finding":"IRF5 directly regulates plasma cell commitment by binding to an IRF site in the Prdm1 promoter and stimulating transcription of Blimp-1 (encoded by Prdm1), a master regulator of plasma cell differentiation. Irf5−/− mice develop age-related splenomegaly with accumulation of CD19+B220− B cells and decreased plasma cells, and ectopic IRF5 reconstitutes Blimp-1 expression.","method":"Irf5−/− mouse genetics, ChIP (IRF5 binding to Prdm1 promoter), reporter assay, ectopic expression rescue, flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct binding, KO phenotype, rescue experiment, multiple orthogonal methods","pmids":["20176957"],"is_preprint":false},{"year":2012,"finding":"IRF5 directly binds to the IRF site in the ikzf1 (Ikaros) promoter and inhibits IRF8-mediated transcriptional activation of ikzf1, thereby reducing Ikaros expression and enabling IgG2a/c class switching in B cells. IRF5-deficient mice have attenuated IgG2a/c responses, which is cell-intrinsically dependent on IRF5 in B cells.","method":"Irf5−/− mouse genetics, SCID reconstitution, ChIP (IRF5 binding to ikzf1 promoter), reporter assay, in vitro class-switching assay","journal":"Genes and immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP binding, reporter assay, in vivo reconstitution proving B cell-intrinsic mechanism","pmids":["22535200"],"is_preprint":false},{"year":2008,"finding":"IRF5 is required for death receptor (Fas/CD95) signaling in a cell-type-specific manner: Irf5−/− mice are resistant to hepatic apoptosis induced by Fas-activating antibody. IRF5 functions upstream of caspase 8 activation in Fas-DR signaling. TRAIL also activates IRF5 phosphorylation and nuclear translocation, leading to transactivation of death receptor signaling components.","method":"Irf5−/− mouse model, in vivo Fas-activating antibody challenge, caspase 8 activation assay, IRF5 phosphorylation and nuclear translocation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with specific apoptotic phenotype, epistasis placing IRF5 upstream of caspase 8, replicated with TRAIL in separate study (PMID 19028697)","pmids":["18268344","19028697"],"is_preprint":false},{"year":2010,"finding":"Both HDACs and histone acetyltransferases (HATs) associate with IRF5; HDAC activity is required for IRF5-mediated transactivation of ISRE, IFNA, and IL6 promoters (but not TNFα). IRF5 phosphorylation is dependent on HAT association, resulting in IRF5 acetylation. Virus triggers dynamic conversion of an IRF5-mediated silencing complex to an activating complex at target promoters.","method":"Co-immunoprecipitation (IRF5 with HDAC1, Sin3a, HATs), HDAC inhibitor (TSA) treatment, reporter assay, domain mapping","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP and functional reporter data, single lab, moderate mechanistic detail","pmids":["20935208"],"is_preprint":false},{"year":2009,"finding":"The KSHV-encoded vIRF-3 physically interacts with cellular IRF5 via a central double helix motif, inhibiting IRF5 binding to interferon-responsive promoter elements and blocking IRF5-mediated transcriptional transactivation and apoptosis induction.","method":"Co-immunoprecipitation, reporter assay, vIRF-3 silencing, domain mutagenesis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP with domain mapping, functional reporter assay, single lab","pmids":["19129183"],"is_preprint":false},{"year":2012,"finding":"KAP1/TRIM28 is an IRF5-interacting protein (identified by affinity purification/mass spectrometry) that acts as a transcriptional co-repressor of IRF5 function. The interaction interface maps to the N-terminus of IRF5 (DNA-binding domain plus intrinsically disordered region). IRF5 also forms complexes with methyltransferase SETDB1. KAP1 knockdown in human M1 macrophages potentiates IRF5-mediated TNF expression.","method":"Affinity purification coupled to mass spectrometry, co-immunoprecipitation, domain mapping, siRNA knockdown, gene expression assay","journal":"Immunobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — AP-MS interaction discovery confirmed by co-IP and functional knockdown, single lab","pmids":["22995936"],"is_preprint":false},{"year":2016,"finding":"Lyn kinase physically interacts with IRF5 and inhibits K63-linked ubiquitination and phosphorylation of IRF5 in the TLR-MyD88 pathway, suppressing IRF5 transcriptional activity independently of Lyn's kinase activity. Monoallelic deletion of Irf5 alleviates hyperproduction of cytokines in Lyn−/− dendritic cells.","method":"Co-immunoprecipitation, ubiquitination assay, kinase-dead Lyn mutant analysis, Lyn−/−Irf5+/− genetic compound mouse","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, ubiquitination assay, kinase-independent mechanism validated with kinase-dead mutant, in vivo genetic rescue","pmids":["27521268"],"is_preprint":false},{"year":2016,"finding":"Upon NOD2 stimulation in human macrophages, IRF5 binds RIP2, IRAK1, and TRAF6, and is required for optimal Akt2 activation, which drives expression of glycolytic pathway genes, HIF1A, and M1 polarization. IRF5 disease-risk variants (rs2004640/rs2280714 TT/TT) confer increased Akt2 activation and glycolysis.","method":"Co-immunoprecipitation (IRF5 with RIP2/IRAK1/TRAF6), siRNA knockdown, Akt2 kinase assay, gene expression analysis, human macrophage genotyping","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of IRF5 signaling complex, functional Akt2 activation assay, human primary cells, single lab","pmids":["27545875"],"is_preprint":false},{"year":2014,"finding":"IRF5 directly binds the P2rx4 gene promoter in microglia upon fibronectin stimulation, driving de novo P2X4R expression. IRF8 is an upstream regulator of IRF5 expression in spinal microglia, defining an IRF8→IRF5 transcriptional axis. Irf5−/− mice fail to upregulate spinal P2X4R after peripheral nerve injury and show resistance to neuropathic pain hypersensitivity.","method":"ChIP (IRF5 binding to P2rx4 promoter), Irf5−/− mouse genetics, behavioral pain assays, IRF8/IRF5 expression analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP binding to promoter, KO mouse with specific phenotype, upstream regulator identified","pmids":["24818655"],"is_preprint":false},{"year":2013,"finding":"IRF5 and IRF7 (along with IRF3) coordinately regulate the type I IFN and ISG response in myeloid dendritic cells downstream of MAVS signaling. In Irf3×Irf5×Irf7 triple-KO mDCs, essentially no ISG induction was detected after WNV infection or TLR stimulation, equivalent to Mavs−/− mDCs, establishing an MAVS→IRF5 signaling link independent of IRF3 and IRF7.","method":"Triple-KO mouse genetics (Irf3−/−×Irf5−/−×Irf7−/−), microarray transcriptomics, in vitro infection assays, in vivo pathogenesis studies","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with triple-KO and comparison to Mavs−/−, microarray validation, in vivo phenotype","pmids":["23300459"],"is_preprint":false},{"year":2020,"finding":"TASL (encoded by CXorf21) interacts with the endolysosomal transporter SLC15A4 and contains a conserved pLxIS motif that mediates recruitment and activation of IRF5. Loss of TASL specifically impairs IRF pathway activation (IRF5) by TLR7, TLR8, and TLR9, without affecting NF-κB or MAPK signaling, identifying TASL as an innate immune adaptor linking endolysosomal TLRs to IRF5.","method":"TASL/SLC15A4 deletion in primary and transformed human immune cells, TASL mutagenesis (pLxIS motif), co-immunoprecipitation, cytokine/signaling assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — extensive mutagenesis, KO in primary human cells, clear mechanistic dissection from NF-κB pathway, replicated in multiple cell types","pmids":["32433612"],"is_preprint":false},{"year":2021,"finding":"PYK2 (PTK2B) phosphorylates IRF5 and is required for endogenous IRF5 activation in macrophages. PYK2-deficient macrophages and pharmacological PYK2 inhibition (defactinib) reduce IRF5 activation and inflammatory gene expression, and defactinib reduces pro-inflammatory cytokines in human colon biopsies from ulcerative colitis patients.","method":"Kinase inhibitor library screen, PYK2-deficient macrophages, defactinib pharmacological inhibition, transcriptomic profiling, ex vivo human colon biopsies, mouse colitis model","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic and pharmacological KO, transcriptomic similarity to IRF5 deficiency, ex vivo human tissue validation, in vivo mouse model","pmids":["34795257"],"is_preprint":false},{"year":2017,"finding":"IRAK4 kinase activity controls IRF5 activation in the TLR-MyD88 pathway: IRAK4 inhibition abolishes IRF5 nuclear translocation and prevents IRF5 binding to inflammatory cytokine promoters. IRAK4 acts through TAK1→IKKβ→IRF5 phosphorylation, while NF-κB nuclear translocation is not blocked by IRAK4 inhibition.","method":"Selective IRAK4 inhibitor in human primary monocytes, ChIP (IRF5 at cytokine promoters), transcriptomics, signaling pathway analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition of IRAK4 with ChIP and transcriptomics readout, epistasis established by inhibitor cascade","pmids":["28924041"],"is_preprint":false},{"year":2018,"finding":"IRF5 homodimer DNA-binding specificity was characterized by protein-binding microarrays; IRF5 homodimers do not bind the ISRE-variants present in IFN gene VREs, due to a critical specificity-determining residue. Mutational analysis reveals this residue inhibits IRF5 binding to IFN promoter ISRE-variants, distinguishing IRF5 from IRF3/IRF7 homodimers.","method":"Protein-binding microarrays (PBMs), site-directed mutagenesis, reporter gene assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted DNA-binding with PBMs, mutagenesis validation, multiple IRF comparators","pmids":["29361124"],"is_preprint":false},{"year":2015,"finding":"IRF5 directly binds promoters of TGFβ1 (TGFB1) in adipose tissue macrophages and represses its transcription; genome-wide gene expression analysis in Irf5-deficient mice placed TGFβ1 as a direct IRF5 target, linking IRF5 to adipose tissue expansion and insulin sensitivity during obesity.","method":"Genome-wide gene expression analysis (ChIP/RNA-seq implied), Irf5−/− mouse model on high-fat diet, adipose tissue macrophage isolation","journal":"Nature medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genome-wide analysis with in vivo KO phenotype; direct ChIP for TGFB1 not explicitly stated in abstract, single lab","pmids":["25939064"],"is_preprint":false},{"year":2014,"finding":"BCR-ABL kinase interacts with IRF5 in CML cells and induces tyrosine phosphorylation of IRF5, reducing its transcriptional activity. Imatinib treatment partially restores IRF5 transcriptional activity. A BCR-ABL consensus site mutant (IRF5Y104F) retains significant tyrosine phosphorylation, suggesting additional phosphorylation sites or downstream pathways.","method":"Co-immunoprecipitation (IRF5-BCR-ABL), phosphotyrosine immunoblot, imatinib treatment, site-directed mutagenesis, reporter assay, cell proliferation assay","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP and phosphorylation assay, mutagenesis, functional readout, single lab","pmids":["24445143"],"is_preprint":false},{"year":2011,"finding":"IRF4 negatively regulates IRF5 at the transcriptional level by binding to the IRF5 promoter, repressing its reporter activity; IRF4 knockdown leads to high IRF5 expression and growth inhibition in EBV-transformed B cells, while knockdown of IRF5 rescues IRF4 knockdown-mediated growth inhibition.","method":"ChIP (IRF4 binding to IRF5 promoter), reporter assay, siRNA knockdown, ectopic overexpression, cell growth assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP binding, reporter assay, epistatic rescue experiment, single lab","pmids":["21454650"],"is_preprint":false},{"year":2006,"finding":"IRF5 is not activated by viral infection directly (unlike IRF3), as assessed by phosphorylation, dimerization, nuclear translocation, CBP binding, and DNA recognition assays. However, ectopic expression of TBK1 or IKKε does activate IRF5. Constitutively active IRF5 promotes apoptosis that is inhibited by Bcl-xL but not dominant-negative FADD, placing IRF5 apoptosis in a FADD-independent pathway.","method":"Phosphorylation assay, nuclear translocation assay, dimerization assay, CBP binding assay, DNA binding assay, apoptosis assay with Bcl-xL and DN-FADD","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple assays for IRF5 activation, clear negative result for viral infection, pathway placement by dominant-negative approach","pmids":["16751392"],"is_preprint":false},{"year":2015,"finding":"Higher basal IRF5 protein levels in female pDCs correlate with higher TLR7-mediated IFN-α production. Delivery of recombinant IRF5 into human primary pDCs directly increases TLR7-mediated IFN-α secretion. Genetic ablation of Esr1 (estrogen receptor 1) in hematopoietic cells or DC lineage reduces Irf5 mRNA in pDCs and IFN-α production, establishing ESR1-mediated transcriptional regulation of IRF5.","method":"Recombinant IRF5 protein delivery into primary human pDCs, conditional Esr1 KO mice, mRNA correlation analysis, IFN-α secretion assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein delivery experiment, conditional KO, multiple orthogonal approaches, single lab","pmids":["26519527"],"is_preprint":false},{"year":2020,"finding":"IRF5 promotes differentiation of Ly6Chi monocytes into CD11c+ macrophages in the colon and controls production of antimicrobial and inflammatory mediators. IRF5 deficiency in mononuclear phagocytes ameliorates Helicobacter hepaticus-induced colitis, established via bone marrow chimera and single-cell RNA-sequencing.","method":"Irf5−/− mouse genetics, MNP-conditional IRF5 deletion, bone marrow chimera, single-cell RNA-sequencing, H. hepaticus colitis model","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-specific KO, scRNA-seq for mechanistic characterization, in vivo disease model, multiple orthogonal approaches","pmids":["32444476"],"is_preprint":false},{"year":2022,"finding":"CXCL4 costimulation synergistically activates TBK1 and IKKε, which are repurposed toward an inflammatory response via coupling with IRF5, leading to amplified inflammatory gene transcription. This CXCL4+TLR8 costimulation induces chromatin remodeling and de novo enhancer activation associated with inflammatory genes in human monocytes/macrophages.","method":"TBK1/IKKε/IRF5 signaling assays, ChIP-seq (chromatin remodeling), ATAC-seq (de novo enhancers), cytokine production assay in human monocytes/macrophages","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq and signaling biochemistry, human primary cells, multiple orthogonal methods","pmids":["35701499"],"is_preprint":false},{"year":2023,"finding":"The autoimmune pleiotropic SNP rs4728142 modulates IRF5 alternative promoter usage: the rs4728142-containing region interacts with the IRF5 alternative promoter in an allele-specific manner via chromatin looping mediated by ZBTB3, promoting IRF5-short transcript expression at the risk allele and resulting in IRF5 overactivation and M1 macrophage polarization.","method":"Chromatin conformation capture (chromatin looping assay), allele-specific reporter assay, ZBTB3 functional analysis, IRF5 transcript quantification, macrophage polarization assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — chromatin looping established mechanistically with allele-specific readout, ZBTB3 identified as structural regulator, functional macrophage polarization outcome","pmids":["36869052"],"is_preprint":false},{"year":2019,"finding":"IRF5 and IRF4 form a regulatory axis in microglia controlling pro- and anti-inflammatory responses after cerebral ischemia: down-regulation of IRF5 increases IRF4 expression and enhances M2 activation, while down-regulation of IRF4 increases IRF5 and M1 activation. The two IRFs mutually suppress each other in an oscillating pattern.","method":"siRNA knockdown, lentiviral overexpression, conditional KO (cKO), middle cerebral artery occlusion stroke model, flow cytometry, RT-PCR, multiplex cytokine analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with both siRNA and conditional KO, in vivo model, multiple readouts including in vitro and in vivo assays","pmids":["31892541"],"is_preprint":false},{"year":2021,"finding":"IRAK4 phosphorylates both IRF5 and IRF4 in microglia and forms a Myddosome complex with MyD88/IRF5/IRF4. IRAK4 inhibition reduces IRF5/IRF4 phosphorylation and nuclear translocation, quenches microglial pro-inflammatory responses, and increases neuronal viability after ischemia.","method":"Co-immunoprecipitation (Myddosome complex), Western blot for phospho-IRF5/IRF4, IRAK4 inhibitor (ND2158), SIM-A9 microglial cell line and primary microglia, OGD model","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP establishing complex, phosphorylation assays, pharmacological inhibition, single lab","pmids":["33573200"],"is_preprint":false},{"year":2019,"finding":"IRF5 directly binds promoters of M1 macrophage-associated genes Ccl4, Ccl5, Tnf, and Il12b in myeloid cells during necrotizing enterocolitis, as shown by chromatin immunoprecipitation. Myeloid-specific Irf5 deficiency prevents experimental NEC by inhibiting M1 macrophage polarization and reducing intestinal epithelial apoptosis.","method":"ChIP (IRF5 binding to Ccl4, Ccl5, Tnf, Il12b promoters), myeloid-specific Irf5 KO, murine NEC model, immunohistochemistry","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP binding evidence, cell-specific KO with defined molecular and phenotypic readout","pmids":["31086271"],"is_preprint":false},{"year":2018,"finding":"IRF5 drives TLR7-mediated IFN-α production in plasmacytoid dendritic cells and inflammatory cytokine production in myeloid cells downstream of TLR7 and possibly RIG-I, but independently of type I IFN production and virus replication. Human iPSC-derived DCs with biallelic IRF5 mutations show impaired virus-induced inflammatory cytokine production.","method":"Irf5−/− mouse in vivo IAV infection model, human iPSC with biallelic IRF5 mutations (iPSC-DCs and macrophages), CyTOF, cytokine assays","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO mouse and human iPSC genetic model, multiple cell types, CyTOF validation","pmids":["32075938"],"is_preprint":false},{"year":2021,"finding":"B cell receptor and TLR7 signaling synergize to promote IRF5 phosphorylation and increase IRF5 protein expression through independently regulated mechanisms. TLR7-dependent IRF5 nuclear translocation is reduced in B cells from IRF5-heterozygous mice. IRF5 drives IL-6 and TNF-α production in B cells, required for germinal center responses, and a critical threshold of IRF5 in B cells is required for lupus pathogenesis.","method":"Conditional B cell-specific Irf5 KO, IRF5 phosphorylation assay, nuclear translocation imaging, IL-6/TNF-α production assay, multiple murine lupus models","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO, multiple lupus models, mechanistic dissection of BCR and TLR7 signal convergence on IRF5","pmids":["34197340"],"is_preprint":false},{"year":2020,"finding":"IRF5 in CD4+ T cells is required for the optimal assembly of the TCR-initiated signaling complex and downstream signaling, and binds to promoters of Th1- and Th17-associated transcription factors and cytokines at later timepoints. IRF5 also regulates chemokine receptor-initiated signaling and T cell migration. Irf5-deficient CD4+ T cells show reduced Th1/Th17 cytokines and increased Th2 cytokines in vivo.","method":"T cell-conditional IRF5 deletion, TCR signaling complex immunoprecipitation, ChIP (IRF5 binding to Th1/Th17 gene promoters), migration assay, colitis model","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO, ChIP binding, signaling complex IP, migration and in vivo colitis assays","pmids":["32610123"],"is_preprint":false},{"year":2020,"finding":"Cell-penetrating peptides (CPPs) designed to disrupt IRF5 homodimerization directly bind to endogenous IRF5, are cell permeable, and inhibit IRF5-mediated IFN-α production in plasmacytoid dendritic cells. CPP activity corresponds to reduced nuclear phospho-Ser462 IRF5 without affecting overall pIRF5 levels, placing CPP action downstream of phosphorylation at the dimerization step.","method":"Biochemical binding assay, live-cell imaging, IRF5 homodimerization assay, IFN-α production assay, flow cytometry for nuclear pIRF5","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated, mechanistic placement downstream of phosphorylation, functional readout in primary cells, single lab","pmids":["32440537"],"is_preprint":false},{"year":2023,"finding":"CLEC2D forms homodimers and heterodimers with TLR2; both dimeric forms mediate β-glucan-induced ubiquitination and degradation of MyD88, inhibiting IRF5 activation and IL-12 production. Clec2d-deficient female mice show increased IL-12 production and resistance to Candida albicans infection.","method":"Co-immunoprecipitation (CLEC2D-TLR2 dimerization), quantitative ligand binding assay, ubiquitination assay, Clec2d−/− mouse model, C. albicans infection model, cytokine assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP for dimerization, ubiquitination biochemistry, in vivo KO with mechanistic pathway dissection","pmids":["37872182"],"is_preprint":false}],"current_model":"IRF5 is a signal-dependent transcription factor that, upon activation through the TLR-MyD88 pathway (requiring TRAF6, IRAK4, TAK1, and IKKβ-mediated phosphorylation at Ser445/Ser462), undergoes K63-linked ubiquitination, homodimerization, and nuclear translocation—a process negatively regulated by Lyn kinase, IKKα, KAP1/TRIM28, and CLEC2D; in the nucleus, IRF5 directly binds ISRE and composite PU.1:ISRE motifs at promoters of proinflammatory cytokines (IL-12, IL-23, TNF-α, IL-6) and represses IL-10, thereby driving M1 macrophage polarization, Th1/Th17 responses, B cell plasmablast differentiation, and death-receptor-mediated apoptosis, while its endolysosomal activation by TLR7/8/9 is specifically mediated by the adaptor TASL via SLC15A4."},"narrative":{"mechanistic_narrative":"IRF5 is a signal-dependent transcription factor that converts innate immune receptor engagement into proinflammatory gene programs, acting downstream of the TLR-MyD88 pathway through physical association with MyD88 and TRAF6 to drive nuclear translocation and induction of IL-6, IL-12, and TNF-α, with Irf5-deficient mice failing to mount these responses and resisting endotoxin shock [PMID:15665823]. Its activity is gated by a defined activation cascade: IRAK4 acts upstream through TAK1→IKKβ, which phosphorylates IRF5 at Ser445 and Ser462 to trigger dimerization and nuclear entry [PMID:25326420, PMID:25326418, PMID:28924041], with PYK2 also required for endogenous IRF5 activation in macrophages [PMID:34795257]; the protein carries a constitutive-activation domain, an autoinhibitory domain, dual nuclear localization signals, and a CRM1-dependent nuclear export signal that together govern its shuttling [PMID:12138184, PMID:15556946]. In the nucleus IRF5 binds ISRE and composite PU.1:ISRE motifs—cooperating physically with RelA/NF-κB p65—to activate IL-12/IL-23 family genes while repressing IL-10, thereby programming M1 macrophage polarization [PMID:21240265, PMID:25159141], and a specificity-determining residue excludes IRF5 homodimers from the IFN-promoter ISRE variants bound by IRF3/IRF7 [PMID:29361124]. Beyond myeloid cells, IRF5 directly drives plasma cell commitment via the Prdm1/Blimp-1 promoter and B-cell class switching, supports Th1/Th17 differentiation and TCR signaling in CD4+ T cells, and mediates Fas/TRAIL death-receptor apoptosis upstream of caspase-8 [PMID:20176957, PMID:22535200, PMID:18268344, PMID:19028697, PMID:32610123]. Endolysosomal TLR7/8/9 signaling to IRF5 is routed through the adaptor TASL, which binds SLC15A4 and recruits IRF5 via a pLxIS motif [PMID:32433612]. IRF5 output is restrained by multiple negative regulators, including IKKα (which blocks the K63-ubiquitination required for activity), Lyn kinase, KAP1/TRIM28, and the CLEC2D–TLR2 axis that degrades MyD88 [PMID:19786094, PMID:27521268, PMID:22995936, PMID:37872182]. Through these activities IRF5 is a central driver of inflammatory disease, with risk-associated promoter and looping variants increasing IRF5 expression and M1 polarization [PMID:36869052].","teleology":[{"year":2002,"claim":"Established IRF5 as a DNA-damage-responsive transcription factor and defined the domain architecture and phosphosites needed for its transactivation, framing it as an inducible, phosphorylation-gated regulator before its innate-immune role was known.","evidence":"EMSA/reporter assays placing IRF5 as a direct p53 target, plus deletion and site-directed mutagenesis mapping activation/autoinhibitory domains and Ser477/Ser480","pmids":["11973653","12138184"],"confidence":"High","gaps":["The physiological upstream kinase for Ser477/480 was not identified","Connection between p53-induced IRF5 and innate immune signaling not addressed"]},{"year":2004,"claim":"Resolved how IRF5 subcellular distribution is controlled, showing a CRM1-dependent nuclear export signal restrains it and that TBK1/IKKε phosphorylation, unlike for IRF3, does not activate it.","evidence":"Leptomycin B treatment, NES mutagenesis with subcellular imaging, and co-transfection kinase assays","pmids":["15556946"],"confidence":"High","gaps":["Did not identify the activating kinase","Mechanism by which most IRF5 is held cytoplasmic in resting cells not fully defined"]},{"year":2005,"claim":"Identified the core innate-immune function of IRF5 as a MyD88/TRAF6-coupled transcription factor essential for TLR-induced proinflammatory cytokine production in vivo.","evidence":"Irf5-/- mouse genetics, co-IP of IRF5 with MyD88/TRAF6, nuclear translocation and cytokine assays, endotoxin shock challenge","pmids":["15665823"],"confidence":"High","gaps":["Did not define the activating phosphorylation event downstream of MyD88/TRAF6","DNA-binding site preference at endogenous promoters not yet mapped"]},{"year":2006,"claim":"Clarified that IRF5 is not directly virus-activated like IRF3 and that constitutively active IRF5 drives FADD-independent apoptosis, distinguishing IRF5 from other IRFs functionally.","evidence":"Phosphorylation/dimerization/nuclear-translocation/DNA-binding assays and apoptosis assays with Bcl-xL and dominant-negative FADD","pmids":["16751392"],"confidence":"Medium","gaps":["Endogenous activating stimuli not defined in this study","Apoptotic effector mechanism downstream of IRF5 not resolved"]},{"year":2009,"claim":"Began dissecting the modifications gating IRF5 activity, showing IKKα phosphorylation induces dimerization but inhibits activity by blocking the K63-ubiquitination IRF5 requires.","evidence":"Co-IP, in vitro kinase and ubiquitination assays, reporter assays","pmids":["19786094"],"confidence":"Medium","gaps":["E3 ligase mediating K63 ubiquitination not identified","Limited independent replication of the IKKα inhibitory role"]},{"year":2010,"claim":"Showed IRF5 transactivation is coupled to chromatin-modifying complexes, with HDAC- and HAT-containing assemblies dynamically converting an IRF5 silencing complex to an activating one at target promoters.","evidence":"Co-IP with HDAC1/Sin3a/HATs, TSA inhibitor treatment, reporter assays, domain mapping","pmids":["20935208"],"confidence":"Medium","gaps":["Promoter-specific recruitment of each complex not fully defined","Single-lab data without genome-wide validation"]},{"year":2011,"claim":"Defined IRF5 as the molecular driver of M1 macrophage polarization by directly activating IL-12/IL-23 family genes and repressing IL-10.","evidence":"ChIP at target promoters, IRF5 overexpression, expression profiling, polarization assays","pmids":["21240265"],"confidence":"High","gaps":["Mechanism of IL-10 repression not detailed","Cofactor requirements at activating versus repressing targets not resolved"]},{"year":2012,"claim":"Extended IRF5's transcriptional roles into B-cell biology (class switching via repressing IRF8-driven Ikaros) and identified KAP1/TRIM28 and SETDB1 as corepressors of IRF5.","evidence":"Irf5-/- mice with SCID reconstitution and ChIP at ikzf1; AP-MS and functional knockdown for KAP1/TRIM28","pmids":["22535200","22995936"],"confidence":"Medium","gaps":["KAP1/SETDB1-mediated repression mechanism at endogenous IRF5 targets not fully resolved","How IRF5 switches between activating and IRF8-antagonizing modes unclear"]},{"year":2014,"claim":"Identified the principal activating kinase axis as IKKβ phosphorylating IRF5 at Ser445 and Ser462 downstream of TAK1, the events required for dimerization, nuclear translocation, and cytokine/IFNβ output.","evidence":"In vitro kinase assays with recombinant IKKβ, MS phosphosite mapping, phospho-specific antibodies, Ser-to-Ala mutants, siRNA and pharmacological inhibition of IKKβ/TAK1","pmids":["25326420","25326418"],"confidence":"High","gaps":["E3 ligase for the required K63 ubiquitination still unidentified","Whether both serines are phosphorylated simultaneously or sequentially not resolved"]},{"year":2014,"claim":"Mapped IRF5's genomic engagement and a key DNA-binding cofactor, showing it uses composite PU.1:ISRE motifs and physically partners with RelA to control a subset of inflammatory genes.","evidence":"Genome-wide ChIP-seq, protein:DNA microarrays, reciprocal co-IP, transcriptomics in IRF5- and RelA-deficient macrophages","pmids":["25159141"],"confidence":"High","gaps":["Generality of the RelA dependency across cell types not established","Determinants selecting composite versus ISRE-only sites not defined"]},{"year":2014,"claim":"Broadened IRF5's direct-target repertoire to neuronal/glial contexts, defining an IRF8→IRF5→P2X4R axis driving neuropathic pain.","evidence":"ChIP at the P2rx4 promoter, Irf5-/- mice, behavioral pain assays, IRF8/IRF5 expression analysis","pmids":["24818655"],"confidence":"High","gaps":["Signal triggering microglial IRF5 activation in vivo not pinpointed","Whether IRF8 regulates IRF5 directly at the transcriptional level not shown"]},{"year":2013,"claim":"Placed IRF5 within the cytosolic RNA-sensing pathway, showing IRF3/IRF5/IRF7 collectively are required for MAVS-dependent type I IFN/ISG responses in myeloid DCs.","evidence":"Irf3xIrf5xIrf7 triple-KO mouse genetics, microarray transcriptomics, viral infection and pathogenesis assays","pmids":["23300459"],"confidence":"High","gaps":["The unique non-redundant IRF5 contribution versus IRF3/IRF7 not isolated","Direct MAVS-to-IRF5 biochemical link not demonstrated"]},{"year":2015,"claim":"Established additional negative-target and disease links, with IRF5 directly repressing TGFβ1 in adipose macrophages affecting metabolic disease, and ESR1-mediated transcriptional control of IRF5 underlying sex-biased IFN-α responses.","evidence":"Genome-wide expression analysis in Irf5-/- mice on high-fat diet; recombinant IRF5 delivery into human pDCs plus conditional Esr1 KO","pmids":["25939064","26519527"],"confidence":"Medium","gaps":["Direct ChIP at TGFB1 not explicitly demonstrated","Mechanism of ESR1-driven IRF5 transcription not detailed"]},{"year":2016,"claim":"Identified key negative regulators and an additional receptor input, showing Lyn kinase suppresses IRF5 K63-ubiquitination/phosphorylation kinase-independently, and that NOD2 engages IRF5 with RIP2/IRAK1/TRAF6 to drive Akt2-dependent glycolysis and M1 polarization.","evidence":"Co-IP, ubiquitination assays, kinase-dead Lyn mutant, Lyn-/-Irf5+/- compound mice; co-IP of IRF5 signaling complex with Akt2 assays and human macrophage genotyping","pmids":["27521268","27545875"],"confidence":"High","gaps":["How Lyn physically blocks ubiquitination mechanistically not resolved","Direct versus indirect IRF5–Akt2 connection not fully defined"]},{"year":2017,"claim":"Placed IRAK4 kinase activity at the apex of the MyD88→TAK1→IKKβ→IRF5 cascade, separable from NF-κB, validating IRF5 activation as a targetable inflammatory node.","evidence":"Selective IRAK4 inhibition in human monocytes with ChIP of IRF5 at cytokine promoters and transcriptomics","pmids":["28924041"],"confidence":"High","gaps":["Whether IRAK4 phosphorylates IRF5 directly or only via the cascade not distinguished here","Selectivity of downstream gene effects not exhaustively mapped"]},{"year":2018,"claim":"Explained the molecular basis for IRF5's distinct promoter selectivity, identifying a specificity-determining residue that excludes IRF5 homodimers from the IFN-gene ISRE variants bound by IRF3/IRF7.","evidence":"Protein-binding microarrays of IRF5 homodimers, site-directed mutagenesis, reporter assays","pmids":["29361124"],"confidence":"High","gaps":["In vivo consequences of the specificity residue not tested","How heterodimerization or cofactors alter this specificity not addressed"]},{"year":2019,"claim":"Demonstrated context-specific direct targets and a reciprocal IRF5/IRF4 polarization switch, with IRF5 binding M1 chemokine/cytokine promoters in intestinal disease and mutually antagonizing IRF4 in microglia.","evidence":"ChIP at Ccl4/Ccl5/Tnf/Il12b with myeloid-specific Irf5 KO NEC model; siRNA/overexpression/cKO with stroke model for the IRF5/IRF4 axis","pmids":["31086271","31892541"],"confidence":"High","gaps":["Molecular basis of mutual IRF5/IRF4 suppression not fully defined","Upstream cues setting the IRF5:IRF4 balance unclear"]},{"year":2020,"claim":"Identified TASL/SLC15A4 as the missing adaptor linking endolysosomal TLR7/8/9 specifically to IRF5, and extended IRF5's roles into monocyte-to-macrophage differentiation, CD4+ T-cell TCR signaling/Th1-Th17 programs, and human antiviral immunity.","evidence":"TASL/SLC15A4 deletion and pLxIS-motif mutagenesis in human immune cells; Irf5-/- and conditional KO mice with scRNA-seq, colitis and infection models, human iPSC-DCs","pmids":["32433612","32444476","32610123","32075938"],"confidence":"High","gaps":["Structural basis of TASL pLxIS recruitment of IRF5 not resolved","How a single factor coordinates such distinct cell-type programs unclear"]},{"year":2021,"claim":"Identified additional activating kinases and signal-convergence mechanisms, showing PYK2 is required for endogenous IRF5 activation, IRAK4 forms a MyD88/IRF5/IRF4 Myddosome in microglia, and BCR plus TLR7 synergize to raise IRF5 phosphorylation/expression to a lupus-relevant threshold in B cells.","evidence":"Kinase inhibitor screen and PYK2-deficient macrophages with defactinib; Myddosome co-IP and IRAK4 inhibition in microglia; B-cell-conditional Irf5 KO across lupus models","pmids":["34795257","33573200","34197340"],"confidence":"High","gaps":["PYK2 phosphosite on IRF5 not mapped","How BCR and TLR7 inputs are integrated quantitatively to set the IRF5 threshold not resolved"]},{"year":2020,"claim":"Established IRF5 dimerization as a druggable step, with cell-penetrating peptides that bind IRF5 and block homodimerization acting downstream of phosphorylation to reduce nuclear pSer462-IRF5 and IFN-α.","evidence":"Biochemical binding, live-cell imaging, dimerization and IFN-α assays, flow cytometry of nuclear pIRF5 in pDCs","pmids":["32440537"],"confidence":"Medium","gaps":["In vivo efficacy and selectivity not established","Structural detail of the disrupted dimer interface not resolved"]},{"year":2023,"claim":"Connected human autoimmune-risk genetics to IRF5 dosage and showed inhibitory checkpoints, with the rs4728142/ZBTB3 looping mechanism raising IRF5-short transcript and M1 polarization, and CLEC2D-TLR2 degrading MyD88 to limit IRF5 activation.","evidence":"Chromatin conformation capture with allele-specific reporters and ZBTB3 analysis; co-IP, ubiquitination assays and Clec2d-/- mice with Candida infection","pmids":["36869052","37872182"],"confidence":"High","gaps":["Functional difference between IRF5-short and full-length isoforms mechanistically incomplete","Whether CLEC2D-driven MyD88 degradation generalizes beyond β-glucan/TLR2 contexts unclear"]},{"year":null,"claim":"The E3 ligase mediating the K63-linked ubiquitination required for IRF5 activation, and a unifying structural model explaining how phosphorylation, ubiquitination, dimerization, and cofactor selection (PU.1, RelA, IRF4/IRF8, KAP1) are integrated across cell types, remain undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No K63 E3 ligase identified despite ubiquitination being mechanistically central","No integrated structural model of the activated IRF5 dimer with cofactors","Determinants directing IRF5 to activating versus repressive target genes unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,7,9,10,33,36]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[6,7,9,22,33]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,5,21]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,5]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,6,7,19,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,5,16,19,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,7,9,10,33]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[11,26]}],"complexes":["Myddosome (MyD88/IRF5/IRF4)","TASL-SLC15A4 complex"],"partners":["MYD88","TRAF6","IKBKB","RELA","TASL","LYN","TRIM28","IRAK4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13568","full_name":"Interferon regulatory factor 5","aliases":[],"length_aa":498,"mass_kda":56.0,"function":"Transcription factor that plays a critical role in innate immunity by activating expression of type I interferon (IFN) IFNA and INFB and inflammatory cytokines downstream of endolysosomal toll-like receptors TLR7, TLR8 and TLR9 (PubMed:11303025, PubMed:15695821, PubMed:22412986, PubMed:25326418, PubMed:32433612). Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters (By similarity). Can efficiently activate both the IFN-beta (IFNB) and the IFN-alpha (IFNA) genes and mediate their induction downstream of the TLR-activated, MyD88-dependent pathway (By similarity). Key transcription factor regulating the IFN response during SARS-CoV-2 infection (PubMed:33440148)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13568/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IRF5","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IRF5","total_profiled":1310},"omim":[{"mim_id":"621294","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 3; ZBTB3","url":"https://www.omim.org/entry/621294"},{"mim_id":"615806","title":"SOLUTE CARRIER FAMILY 15 (OLIGOPEPTIDE TRANSPORTER), MEMBER 4; SLC15A4","url":"https://www.omim.org/entry/615806"},{"mim_id":"614221","title":"BILIARY CIRRHOSIS, PRIMARY, 5; PBC5","url":"https://www.omim.org/entry/614221"},{"mim_id":"614220","title":"BILIARY CIRRHOSIS, PRIMARY, 4; PBC4","url":"https://www.omim.org/entry/614220"},{"mim_id":"612378","title":"SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 13; SLEB13","url":"https://www.omim.org/entry/612378"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/IRF5"},"hgnc":{"alias_symbol":["IRF-5"],"prev_symbol":[]},"alphafold":{"accession":"Q13568","domains":[{"cath_id":"1.10.10.10","chopping":"18-121","consensus_level":"high","plddt":82.4037,"start":18,"end":121},{"cath_id":"2.60.200.10","chopping":"246-432","consensus_level":"high","plddt":93.8104,"start":246,"end":432}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13568","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13568-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13568-F1-predicted_aligned_error_v6.png","plddt_mean":72.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IRF5","jax_strain_url":"https://www.jax.org/strain/search?query=IRF5"},"sequence":{"accession":"Q13568","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13568.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13568/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13568"}},"corpus_meta":[{"pmid":"21240265","id":"PMC_21240265","title":"IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses.","date":"2011","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21240265","citation_count":1058,"is_preprint":false},{"pmid":"15665823","id":"PMC_15665823","title":"Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15665823","citation_count":809,"is_preprint":false},{"pmid":"23300459","id":"PMC_23300459","title":"IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling.","date":"2013","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/23300459","citation_count":256,"is_preprint":false},{"pmid":"12138184","id":"PMC_12138184","title":"Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12138184","citation_count":211,"is_preprint":false},{"pmid":"26519527","id":"PMC_26519527","title":"Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in Women.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26519527","citation_count":209,"is_preprint":false},{"pmid":"15308637","id":"PMC_15308637","title":"Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15308637","citation_count":186,"is_preprint":false},{"pmid":"32433612","id":"PMC_32433612","title":"TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32433612","citation_count":178,"is_preprint":false},{"pmid":"24818655","id":"PMC_24818655","title":"Transcription factor IRF5 drives P2X4R+-reactive microglia gating neuropathic pain.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24818655","citation_count":169,"is_preprint":false},{"pmid":"31892541","id":"PMC_31892541","title":"Microglial IRF5-IRF4 regulatory axis regulates neuroinflammation after cerebral ischemia and impacts stroke outcomes.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31892541","citation_count":154,"is_preprint":false},{"pmid":"25939064","id":"PMC_25939064","title":"Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25939064","citation_count":151,"is_preprint":false},{"pmid":"11973653","id":"PMC_11973653","title":"Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11973653","citation_count":133,"is_preprint":false},{"pmid":"18050197","id":"PMC_18050197","title":"Association of an IRF5 gene functional polymorphism with Sjögren's syndrome.","date":"2007","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/18050197","citation_count":133,"is_preprint":false},{"pmid":"18285424","id":"PMC_18285424","title":"Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations.","date":"2008","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18285424","citation_count":121,"is_preprint":false},{"pmid":"24453413","id":"PMC_24453413","title":"IRF5 is a specific marker of inflammatory macrophages in vivo.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24453413","citation_count":112,"is_preprint":false},{"pmid":"26279299","id":"PMC_26279299","title":"Onco-exaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26279299","citation_count":96,"is_preprint":false},{"pmid":"25159141","id":"PMC_25159141","title":"IRF5:RelA interaction targets inflammatory genes in macrophages.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25159141","citation_count":92,"is_preprint":false},{"pmid":"27545875","id":"PMC_27545875","title":"IRF5 and IRF5 Disease-Risk Variants Increase Glycolysis and Human M1 Macrophage Polarization by Regulating Proximal Signaling and Akt2 Activation.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27545875","citation_count":89,"is_preprint":false},{"pmid":"27521268","id":"PMC_27521268","title":"Lyn Kinase Suppresses the Transcriptional Activity of IRF5 in the TLR-MyD88 Pathway to Restrain the Development of Autoimmunity.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27521268","citation_count":89,"is_preprint":false},{"pmid":"25326420","id":"PMC_25326420","title":"IKKβ is an IRF5 kinase that instigates inflammation.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25326420","citation_count":88,"is_preprint":false},{"pmid":"25326418","id":"PMC_25326418","title":"Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25326418","citation_count":88,"is_preprint":false},{"pmid":"30199605","id":"PMC_30199605","title":"Advances and challenges in targeting IRF5, a key regulator of inflammation.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/30199605","citation_count":87,"is_preprint":false},{"pmid":"20176957","id":"PMC_20176957","title":"Critical role of IRF-5 in regulation of B-cell differentiation.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20176957","citation_count":87,"is_preprint":false},{"pmid":"28515358","id":"PMC_28515358","title":"IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28515358","citation_count":76,"is_preprint":false},{"pmid":"29361124","id":"PMC_29361124","title":"DNA-binding landscape of IRF3, IRF5 and IRF7 dimers: implications for dimer-specific gene regulation.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29361124","citation_count":72,"is_preprint":false},{"pmid":"23616277","id":"PMC_23616277","title":"IRF-5 and NF-κB p50 co-regulate IFN-β and IL-6 expression in TLR9-stimulated human plasmacytoid dendritic cells.","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23616277","citation_count":71,"is_preprint":false},{"pmid":"20935208","id":"PMC_20935208","title":"Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20935208","citation_count":71,"is_preprint":false},{"pmid":"19028697","id":"PMC_19028697","title":"IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19028697","citation_count":70,"is_preprint":false},{"pmid":"32444476","id":"PMC_32444476","title":"IRF5 guides monocytes toward an inflammatory CD11c+ macrophage phenotype and promotes intestinal inflammation.","date":"2020","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32444476","citation_count":70,"is_preprint":false},{"pmid":"32897883","id":"PMC_32897883","title":"Inhibition of IRF5 hyperactivation protects from lupus onset and severity.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32897883","citation_count":69,"is_preprint":false},{"pmid":"28924041","id":"PMC_28924041","title":"IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28924041","citation_count":67,"is_preprint":false},{"pmid":"19644876","id":"PMC_19644876","title":"Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19644876","citation_count":63,"is_preprint":false},{"pmid":"16751392","id":"PMC_16751392","title":"Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16751392","citation_count":63,"is_preprint":false},{"pmid":"19129183","id":"PMC_19129183","title":"The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19129183","citation_count":63,"is_preprint":false},{"pmid":"22995936","id":"PMC_22995936","title":"KAP1/TRIM28: an inhibitor of IRF5 function in inflammatory macrophages.","date":"2012","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22995936","citation_count":62,"is_preprint":false},{"pmid":"22194884","id":"PMC_22194884","title":"Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22194884","citation_count":62,"is_preprint":false},{"pmid":"29858055","id":"PMC_29858055","title":"Gene Therapy for Neuropathic Pain through siRNA-IRF5 Gene Delivery with Homing Peptides to Microglia.","date":"2018","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/29858055","citation_count":60,"is_preprint":false},{"pmid":"20802013","id":"PMC_20802013","title":"Gender-dependent expression of murine Irf5 gene: implications for sex bias in autoimmunity.","date":"2010","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20802013","citation_count":59,"is_preprint":false},{"pmid":"15556946","id":"PMC_15556946","title":"A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15556946","citation_count":59,"is_preprint":false},{"pmid":"18268344","id":"PMC_18268344","title":"A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18268344","citation_count":58,"is_preprint":false},{"pmid":"18075793","id":"PMC_18075793","title":"The genetics and biology of Irf5-mediated signaling in lupus.","date":"2007","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/18075793","citation_count":57,"is_preprint":false},{"pmid":"18505922","id":"PMC_18505922","title":"Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts.","date":"2008","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/18505922","citation_count":55,"is_preprint":false},{"pmid":"29367853","id":"PMC_29367853","title":"B Cell-Intrinsic Role for IRF5 in TLR9/BCR-Induced Human B Cell Activation, Proliferation, and Plasmablast Differentiation.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29367853","citation_count":54,"is_preprint":false},{"pmid":"26046638","id":"PMC_26046638","title":"IRF-5-Mediated Inflammation Limits CD8+ T Cell Expansion by Inducing HIF-1α and Impairing Dendritic Cell Functions during Leishmania Infection.","date":"2015","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/26046638","citation_count":52,"is_preprint":false},{"pmid":"24928322","id":"PMC_24928322","title":"IRF5-mediated signaling and implications for SLE.","date":"2014","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/24928322","citation_count":50,"is_preprint":false},{"pmid":"22039224","id":"PMC_22039224","title":"Replication of GWAS-identified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5 in disease susceptibility in a Northern European population.","date":"2011","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22039224","citation_count":50,"is_preprint":false},{"pmid":"26598674","id":"PMC_26598674","title":"Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26598674","citation_count":50,"is_preprint":false},{"pmid":"38469055","id":"PMC_38469055","title":"Nicorandil-Pretreated Mesenchymal Stem Cell-Derived Exosomes Facilitate Cardiac Repair After Myocardial Infarction via Promoting Macrophage M2 Polarization by Targeting miR-125a-5p/TRAF6/IRF5 Signaling Pathway.","date":"2024","source":"International journal of nanomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/38469055","citation_count":48,"is_preprint":false},{"pmid":"29860420","id":"PMC_29860420","title":"Regulation and role of the transcription factor IRF5 in innate immune responses and systemic lupus erythematosus.","date":"2018","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29860420","citation_count":48,"is_preprint":false},{"pmid":"32806763","id":"PMC_32806763","title":"Repetitive Intermittent Hyperglycemia Drives the M1 Polarization and Inflammatory Responses in THP-1 Macrophages Through the Mechanism Involving the TLR4-IRF5 Pathway.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32806763","citation_count":48,"is_preprint":false},{"pmid":"22535200","id":"PMC_22535200","title":"Unique contribution of IRF-5-Ikaros axis to the B-cell IgG2a response.","date":"2012","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22535200","citation_count":47,"is_preprint":false},{"pmid":"17133578","id":"PMC_17133578","title":"Analysis of IRF5 gene functional polymorphisms in rheumatoid arthritis.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/17133578","citation_count":46,"is_preprint":false},{"pmid":"32610123","id":"PMC_32610123","title":"T Cell-Intrinsic IRF5 Regulates T Cell Signaling, Migration, and Differentiation and Promotes Intestinal Inflammation.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32610123","citation_count":43,"is_preprint":false},{"pmid":"36165212","id":"PMC_36165212","title":"Inflammatory Microenvironment-Responsive Nanomaterials Promote Spinal Cord Injury Repair by Targeting IRF5.","date":"2022","source":"Advanced healthcare materials","url":"https://pubmed.ncbi.nlm.nih.gov/36165212","citation_count":43,"is_preprint":false},{"pmid":"33563611","id":"PMC_33563611","title":"The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.","date":"2021","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/33563611","citation_count":43,"is_preprint":false},{"pmid":"31086271","id":"PMC_31086271","title":"Irf5 deficiency in myeloid cells prevents necrotizing enterocolitis by inhibiting M1 macrophage polarization.","date":"2019","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31086271","citation_count":43,"is_preprint":false},{"pmid":"23349905","id":"PMC_23349905","title":"RNA-Seq for enrichment and analysis of IRF5 transcript expression in SLE.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23349905","citation_count":42,"is_preprint":false},{"pmid":"32188105","id":"PMC_32188105","title":"Enhanced Adipose Expression of Interferon Regulatory Factor (IRF)-5 Associates with the Signatures of Metabolic Inflammation in Diabetic Obese Patients.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32188105","citation_count":40,"is_preprint":false},{"pmid":"23236436","id":"PMC_23236436","title":"Gene-gene and gene-sex epistatic interactions of MiR146a, IRF5, IKZF1, ETS1 and IL21 in systemic lupus erythematosus.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23236436","citation_count":39,"is_preprint":false},{"pmid":"27759022","id":"PMC_27759022","title":"A critical role for IRF5 in regulating allergic airway inflammation.","date":"2016","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27759022","citation_count":38,"is_preprint":false},{"pmid":"31877114","id":"PMC_31877114","title":"IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31877114","citation_count":37,"is_preprint":false},{"pmid":"35701499","id":"PMC_35701499","title":"CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35701499","citation_count":36,"is_preprint":false},{"pmid":"19896215","id":"PMC_19896215","title":"The gene and virus-induced expression of IRF-5 in grass carp Ctenopharyngodon idella.","date":"2009","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19896215","citation_count":34,"is_preprint":false},{"pmid":"22507190","id":"PMC_22507190","title":"IRF5 promotes the proliferation of human thyroid cancer cells.","date":"2012","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22507190","citation_count":34,"is_preprint":false},{"pmid":"29985675","id":"PMC_29985675","title":"IRF5-mediated immune responses and its implications in immunological disorders.","date":"2018","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29985675","citation_count":33,"is_preprint":false},{"pmid":"22909381","id":"PMC_22909381","title":"IRF5 gene polymorphisms in melanoma.","date":"2012","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22909381","citation_count":33,"is_preprint":false},{"pmid":"19786094","id":"PMC_19786094","title":"IKKalpha negatively regulates IRF-5 function in a MyD88-TRAF6 pathway.","date":"2009","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/19786094","citation_count":33,"is_preprint":false},{"pmid":"21454650","id":"PMC_21454650","title":"Interferon regulatory factor 4 (IRF-4) targets IRF-5 to regulate Epstein-Barr virus transformation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21454650","citation_count":33,"is_preprint":false},{"pmid":"33460643","id":"PMC_33460643","title":"miR-31 from adipose stem cell-derived extracellular vesicles promotes recovery of neurological function after ischemic stroke by inhibiting TRAF6 and IRF5.","date":"2021","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33460643","citation_count":32,"is_preprint":false},{"pmid":"31718015","id":"PMC_31718015","title":"Increased Adipose Tissue Expression of Interferon Regulatory Factor (IRF)-5 in Obesity: Association with Metabolic Inflammation.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31718015","citation_count":31,"is_preprint":false},{"pmid":"21040166","id":"PMC_21040166","title":"Association of IRF5 gene polymorphisms and lupus nephritis in a Chinese population.","date":"2010","source":"Nephrology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/21040166","citation_count":31,"is_preprint":false},{"pmid":"31024565","id":"PMC_31024565","title":"FcγR-TLR Cross-Talk Enhances TNF Production by Human Monocyte-Derived DCs via IRF5-Dependent Gene Transcription and Glycolytic Reprogramming.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31024565","citation_count":31,"is_preprint":false},{"pmid":"31799619","id":"PMC_31799619","title":"Specific enhancer selection by IRF3, IRF5 and IRF9 is determined by ISRE half-sites, 5' and 3' flanking bases, collaborating transcription factors and the chromatin environment in a combinatorial fashion.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31799619","citation_count":31,"is_preprint":false},{"pmid":"30067973","id":"PMC_30067973","title":"IRF-5 Promotes Cell Death in CD4 T Cells during Chronic Infection.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30067973","citation_count":30,"is_preprint":false},{"pmid":"29079574","id":"PMC_29079574","title":"Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29079574","citation_count":30,"is_preprint":false},{"pmid":"33523878","id":"PMC_33523878","title":"TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33523878","citation_count":30,"is_preprint":false},{"pmid":"29578052","id":"PMC_29578052","title":"Diverse mechanisms of IRF5 action in inflammatory responses.","date":"2018","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29578052","citation_count":28,"is_preprint":false},{"pmid":"34197340","id":"PMC_34197340","title":"Monoallelic IRF5 deficiency in B cells prevents murine lupus.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34197340","citation_count":28,"is_preprint":false},{"pmid":"31130331","id":"PMC_31130331","title":"Coordination between innate immune cells, type I IFNs and IRF5 drives SLE pathogenesis.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/31130331","citation_count":28,"is_preprint":false},{"pmid":"24697319","id":"PMC_24697319","title":"Gene-gene interactions of IRF5, STAT4, IKZF1 and ETS1 in systemic lupus erythematosus.","date":"2014","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/24697319","citation_count":27,"is_preprint":false},{"pmid":"34795257","id":"PMC_34795257","title":"Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34795257","citation_count":27,"is_preprint":false},{"pmid":"35958624","id":"PMC_35958624","title":"Detection of neutrophil extracellular traps in patient plasma: method development and validation in systemic lupus erythematosus and healthy donors that carry IRF5 genetic risk.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35958624","citation_count":27,"is_preprint":false},{"pmid":"36869052","id":"PMC_36869052","title":"An autoimmune pleiotropic SNP modulates IRF5 alternative promoter usage through ZBTB3-mediated chromatin looping.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36869052","citation_count":26,"is_preprint":false},{"pmid":"30593537","id":"PMC_30593537","title":"IRF5 Is Required for Bacterial Clearance in Human M1-Polarized Macrophages, and IRF5 Immune-Mediated Disease Risk Variants Modulate This Outcome.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30593537","citation_count":26,"is_preprint":false},{"pmid":"21834935","id":"PMC_21834935","title":"A meta-analysis of the association of IRF5 polymorphism with systemic lupus erythematosus.","date":"2011","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/21834935","citation_count":25,"is_preprint":false},{"pmid":"32075938","id":"PMC_32075938","title":"IRF5 Promotes Influenza Virus-Induced Inflammatory Responses in Human Induced Pluripotent Stem Cell-Derived Myeloid Cells and Murine Models.","date":"2020","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/32075938","citation_count":25,"is_preprint":false},{"pmid":"24445143","id":"PMC_24445143","title":"IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.","date":"2014","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24445143","citation_count":25,"is_preprint":false},{"pmid":"31127629","id":"PMC_31127629","title":"Modulation of macrophage subtypes by IRF5 determines osteoclastogenic potential.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31127629","citation_count":24,"is_preprint":false},{"pmid":"33573200","id":"PMC_33573200","title":"Phosphorylation of Microglial IRF5 and IRF4 by IRAK4 Regulates Inflammatory Responses to Ischemia.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33573200","citation_count":24,"is_preprint":false},{"pmid":"23828296","id":"PMC_23828296","title":"IRF5, IRF8, and IRF7 in human pDCs - the good, the bad, and the insignificant?","date":"2013","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23828296","citation_count":24,"is_preprint":false},{"pmid":"33991749","id":"PMC_33991749","title":"Myeloid cell-specific Irf5 deficiency stabilizes atherosclerotic plaques in Apoe-/- mice.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33991749","citation_count":23,"is_preprint":false},{"pmid":"32582209","id":"PMC_32582209","title":"Potential T Cell-Intrinsic Regulatory Roles for IRF5 via Cytokine Modulation in T Helper Subset Differentiation and Function.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32582209","citation_count":23,"is_preprint":false},{"pmid":"32737976","id":"PMC_32737976","title":"IRF5 Acts as a Potential Therapeutic Marker in Inflammatory Bowel Diseases.","date":"2021","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32737976","citation_count":23,"is_preprint":false},{"pmid":"26294277","id":"PMC_26294277","title":"Genetic association and interaction between the IRF5 and TYK2 genes and systemic lupus erythematosus in the Han Chinese population.","date":"2015","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/26294277","citation_count":23,"is_preprint":false},{"pmid":"30050534","id":"PMC_30050534","title":"IRF5 Is a Key Regulator of Macrophage Response to Lipopolysaccharide in Newborns.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30050534","citation_count":23,"is_preprint":false},{"pmid":"18752149","id":"PMC_18752149","title":"Association of IRF5 gene polymorphisms with rheumatoid arthritis in a Tunisian population.","date":"2008","source":"Scandinavian journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/18752149","citation_count":23,"is_preprint":false},{"pmid":"37290736","id":"PMC_37290736","title":"Shexiang Tongxin Dropping Pill alleviates M1 macrophage polarization-induced inflammation and endothelial dysfunction to reduce coronary microvascular dysfunction via the Dectin-1/Syk/IRF5 pathway.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37290736","citation_count":22,"is_preprint":false},{"pmid":"32440537","id":"PMC_32440537","title":"Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32440537","citation_count":22,"is_preprint":false},{"pmid":"37872182","id":"PMC_37872182","title":"C-type lectin receptor 2d forms homodimers and heterodimers with TLR2 to negatively regulate IRF5-mediated antifungal immunity.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37872182","citation_count":22,"is_preprint":false},{"pmid":"32205184","id":"PMC_32205184","title":"Overexpression of miR-133a-3p inhibits fibrosis and proliferation of keloid fibroblasts by regulating IRF5 to inhibit the TGF-β/Smad2 pathway.","date":"2020","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/32205184","citation_count":22,"is_preprint":false},{"pmid":"30297339","id":"PMC_30297339","title":"Differential and Overlapping Immune Programs Regulated by IRF3 and IRF5 in Plasmacytoid Dendritic Cells.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30297339","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51743,"output_tokens":10369,"usd":0.155382,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21022,"output_tokens":7232,"usd":0.142955,"stage2_stop_reason":"end_turn"},"total_usd":0.298337,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"IRF5 physically interacts with MyD88 and TRAF6, and TLR activation via the TLR-MyD88 pathway results in nuclear translocation of IRF5 to activate transcription of proinflammatory cytokine genes (IL-6, IL-12, TNF-α); Irf5−/− mice show severely impaired cytokine induction by TLR ligands and resistance to lethal endotoxin shock.\",\n      \"method\": \"Irf5−/− mouse genetics, co-immunoprecipitation (IRF5 with MyD88/TRAF6), nuclear translocation assay, cytokine measurement in vivo and in vitro\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction evidence, in vivo KO phenotype with defined molecular mechanism, replicated in multiple TLR contexts\",\n      \"pmids\": [\"15665823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IRF5 contains a constitutive-activation domain (aa 410–489), an autoinhibitory domain (aa 490–539), and two functional nuclear localization signals (N- and C-terminal). Serine residues 477 and 480 are critical phosphorylation sites required for IRF5 transactivation in virus-infected cells; Ser→Ala mutations dramatically reduced phosphorylation and transcriptional activity.\",\n      \"method\": \"Deletion mutagenesis, site-directed mutagenesis, transient transfection reporter assays, phosphorylation analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of specific residues with direct functional readout, multiple domain-mapping experiments in one study\",\n      \"pmids\": [\"12138184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IRF5 subcellular localization is controlled by a functional CRM1-dependent nuclear export signal (NES); mutation of two leucine residues in the NES results in constitutive nuclear accumulation. IRF5 is phosphorylated by IKKε and TBK1 in co-transfected cells, but this phosphorylation does not lead to nuclear localization or activation of IRF5.\",\n      \"method\": \"CRM1 inhibitor (leptomycin B), NES mutagenesis, subcellular fractionation/imaging, co-transfection kinase assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with direct localization readout, pharmacological validation, clear negative result for TBK1/IKKε-mediated activation\",\n      \"pmids\": [\"15556946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IKKα phosphorylates IRF5 and induces IRF5 dimerization; however, this phosphorylation exerts an inhibitory effect on IRF5 transcriptional activity by blocking K63-linked ubiquitination that is required for IRF5 activity. Alkaline phosphatase interacts with IRF5 and causes its dephosphorylation, suggesting an autoregulatory loop.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, ubiquitination assay, reporter gene assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single lab, co-IP and in vitro kinase assay with functional readout, but limited independent replication\",\n      \"pmids\": [\"19786094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IKKβ phosphorylates IRF5 at serine 445 (S446 in human IRF5 isoform 1) in response to TLR and RIG-I-like receptor stimulation. A point mutation of Ser445 abolished IRF5 activation and cytokine production. IKKβ depletion or pharmacological inhibition prevented IRF5 phosphorylation.\",\n      \"method\": \"In vitro kinase assay with recombinant IKKβ, mass spectrometry phosphosite identification, phospho-specific antibody, site-directed mutagenesis, siRNA knockdown, pharmacological inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with recombinant kinase, MS-identified phosphosite, mutagenesis confirmation, validated with multiple orthogonal methods\",\n      \"pmids\": [\"25326420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IKKβ phosphorylates IRF5 at Ser462 in myeloid cells, inducing IRF5 dimerization and nuclear translocation. The IRF5[Ser462Ala] mutant failed to translocate to the nucleus after TLR7 stimulation. TAK1 acts as an upstream activator of IKKβ in this pathway. IKKβ-mediated IRF5 phosphorylation is required for IFNβ production in plasmacytoid dendritic cells.\",\n      \"method\": \"In vitro kinase assay (IKKβ phosphorylating IRF5 at Ser462), site-directed mutagenesis, siRNA knockdown of IKKβ and TAK1, pharmacological inhibition, nuclear translocation imaging\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, mutagenesis, siRNA and pharmacological inhibition, concordant with PMID 25326420\",\n      \"pmids\": [\"25326418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF5 directly activates transcription of IL-12p40, IL-12p35, and IL-23p19 genes and represses the IL-10 gene in M1 macrophages. IRF5 expression is reversibly induced by inflammatory stimuli and its high expression is characteristic of M1 macrophages, contributing to macrophage polarization plasticity.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) at target gene promoters, IRF5 overexpression, gene expression profiling, macrophage polarization assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct promoter binding plus functional gene expression data, replicated by multiple labs\",\n      \"pmids\": [\"21240265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IRF5 recruits to regulatory elements of inflammatory genes in LPS-stimulated macrophages using a composite PU.1:ISRE motif in vivo. IRF5 physically interacts with RelA (NF-κB p65), and this IRF5:RelA interaction is required for regulation of a subset of key inflammatory genes. The RelA:IRF5 interaction domain was mapped.\",\n      \"method\": \"Genome-wide ChIP-seq, protein:DNA microarrays (in vitro DNA binding), co-immunoprecipitation, gene expression profiling in IRF5- and RelA-deficient macrophages\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq, in vitro DNA binding, reciprocal co-IP, KO macrophage transcriptomics, multiple orthogonal methods\",\n      \"pmids\": [\"25159141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IRF5 is a direct transcriptional target of p53: a p53-binding site in exon 2 of the IRF5 gene binds p53 protein (EMSA), drives p53-dependent reporter activity, and IRF5 mRNA is induced by DNA damage (γ-irradiation, UV, adriamycin) in a p53-dependent manner.\",\n      \"method\": \"Differential display, EMSA, heterologous reporter assay, DNA damage induction in p53+/+ vs p53−/− cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EMSA with direct binding plus functional reporter assay, multiple DNA damage stimuli tested\",\n      \"pmids\": [\"11973653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IRF5 directly regulates plasma cell commitment by binding to an IRF site in the Prdm1 promoter and stimulating transcription of Blimp-1 (encoded by Prdm1), a master regulator of plasma cell differentiation. Irf5−/− mice develop age-related splenomegaly with accumulation of CD19+B220− B cells and decreased plasma cells, and ectopic IRF5 reconstitutes Blimp-1 expression.\",\n      \"method\": \"Irf5−/− mouse genetics, ChIP (IRF5 binding to Prdm1 promoter), reporter assay, ectopic expression rescue, flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct binding, KO phenotype, rescue experiment, multiple orthogonal methods\",\n      \"pmids\": [\"20176957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IRF5 directly binds to the IRF site in the ikzf1 (Ikaros) promoter and inhibits IRF8-mediated transcriptional activation of ikzf1, thereby reducing Ikaros expression and enabling IgG2a/c class switching in B cells. IRF5-deficient mice have attenuated IgG2a/c responses, which is cell-intrinsically dependent on IRF5 in B cells.\",\n      \"method\": \"Irf5−/− mouse genetics, SCID reconstitution, ChIP (IRF5 binding to ikzf1 promoter), reporter assay, in vitro class-switching assay\",\n      \"journal\": \"Genes and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP binding, reporter assay, in vivo reconstitution proving B cell-intrinsic mechanism\",\n      \"pmids\": [\"22535200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF5 is required for death receptor (Fas/CD95) signaling in a cell-type-specific manner: Irf5−/− mice are resistant to hepatic apoptosis induced by Fas-activating antibody. IRF5 functions upstream of caspase 8 activation in Fas-DR signaling. TRAIL also activates IRF5 phosphorylation and nuclear translocation, leading to transactivation of death receptor signaling components.\",\n      \"method\": \"Irf5−/− mouse model, in vivo Fas-activating antibody challenge, caspase 8 activation assay, IRF5 phosphorylation and nuclear translocation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with specific apoptotic phenotype, epistasis placing IRF5 upstream of caspase 8, replicated with TRAIL in separate study (PMID 19028697)\",\n      \"pmids\": [\"18268344\", \"19028697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Both HDACs and histone acetyltransferases (HATs) associate with IRF5; HDAC activity is required for IRF5-mediated transactivation of ISRE, IFNA, and IL6 promoters (but not TNFα). IRF5 phosphorylation is dependent on HAT association, resulting in IRF5 acetylation. Virus triggers dynamic conversion of an IRF5-mediated silencing complex to an activating complex at target promoters.\",\n      \"method\": \"Co-immunoprecipitation (IRF5 with HDAC1, Sin3a, HATs), HDAC inhibitor (TSA) treatment, reporter assay, domain mapping\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP and functional reporter data, single lab, moderate mechanistic detail\",\n      \"pmids\": [\"20935208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The KSHV-encoded vIRF-3 physically interacts with cellular IRF5 via a central double helix motif, inhibiting IRF5 binding to interferon-responsive promoter elements and blocking IRF5-mediated transcriptional transactivation and apoptosis induction.\",\n      \"method\": \"Co-immunoprecipitation, reporter assay, vIRF-3 silencing, domain mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP with domain mapping, functional reporter assay, single lab\",\n      \"pmids\": [\"19129183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KAP1/TRIM28 is an IRF5-interacting protein (identified by affinity purification/mass spectrometry) that acts as a transcriptional co-repressor of IRF5 function. The interaction interface maps to the N-terminus of IRF5 (DNA-binding domain plus intrinsically disordered region). IRF5 also forms complexes with methyltransferase SETDB1. KAP1 knockdown in human M1 macrophages potentiates IRF5-mediated TNF expression.\",\n      \"method\": \"Affinity purification coupled to mass spectrometry, co-immunoprecipitation, domain mapping, siRNA knockdown, gene expression assay\",\n      \"journal\": \"Immunobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — AP-MS interaction discovery confirmed by co-IP and functional knockdown, single lab\",\n      \"pmids\": [\"22995936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Lyn kinase physically interacts with IRF5 and inhibits K63-linked ubiquitination and phosphorylation of IRF5 in the TLR-MyD88 pathway, suppressing IRF5 transcriptional activity independently of Lyn's kinase activity. Monoallelic deletion of Irf5 alleviates hyperproduction of cytokines in Lyn−/− dendritic cells.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, kinase-dead Lyn mutant analysis, Lyn−/−Irf5+/− genetic compound mouse\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, ubiquitination assay, kinase-independent mechanism validated with kinase-dead mutant, in vivo genetic rescue\",\n      \"pmids\": [\"27521268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Upon NOD2 stimulation in human macrophages, IRF5 binds RIP2, IRAK1, and TRAF6, and is required for optimal Akt2 activation, which drives expression of glycolytic pathway genes, HIF1A, and M1 polarization. IRF5 disease-risk variants (rs2004640/rs2280714 TT/TT) confer increased Akt2 activation and glycolysis.\",\n      \"method\": \"Co-immunoprecipitation (IRF5 with RIP2/IRAK1/TRAF6), siRNA knockdown, Akt2 kinase assay, gene expression analysis, human macrophage genotyping\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of IRF5 signaling complex, functional Akt2 activation assay, human primary cells, single lab\",\n      \"pmids\": [\"27545875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IRF5 directly binds the P2rx4 gene promoter in microglia upon fibronectin stimulation, driving de novo P2X4R expression. IRF8 is an upstream regulator of IRF5 expression in spinal microglia, defining an IRF8→IRF5 transcriptional axis. Irf5−/− mice fail to upregulate spinal P2X4R after peripheral nerve injury and show resistance to neuropathic pain hypersensitivity.\",\n      \"method\": \"ChIP (IRF5 binding to P2rx4 promoter), Irf5−/− mouse genetics, behavioral pain assays, IRF8/IRF5 expression analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP binding to promoter, KO mouse with specific phenotype, upstream regulator identified\",\n      \"pmids\": [\"24818655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IRF5 and IRF7 (along with IRF3) coordinately regulate the type I IFN and ISG response in myeloid dendritic cells downstream of MAVS signaling. In Irf3×Irf5×Irf7 triple-KO mDCs, essentially no ISG induction was detected after WNV infection or TLR stimulation, equivalent to Mavs−/− mDCs, establishing an MAVS→IRF5 signaling link independent of IRF3 and IRF7.\",\n      \"method\": \"Triple-KO mouse genetics (Irf3−/−×Irf5−/−×Irf7−/−), microarray transcriptomics, in vitro infection assays, in vivo pathogenesis studies\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with triple-KO and comparison to Mavs−/−, microarray validation, in vivo phenotype\",\n      \"pmids\": [\"23300459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TASL (encoded by CXorf21) interacts with the endolysosomal transporter SLC15A4 and contains a conserved pLxIS motif that mediates recruitment and activation of IRF5. Loss of TASL specifically impairs IRF pathway activation (IRF5) by TLR7, TLR8, and TLR9, without affecting NF-κB or MAPK signaling, identifying TASL as an innate immune adaptor linking endolysosomal TLRs to IRF5.\",\n      \"method\": \"TASL/SLC15A4 deletion in primary and transformed human immune cells, TASL mutagenesis (pLxIS motif), co-immunoprecipitation, cytokine/signaling assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — extensive mutagenesis, KO in primary human cells, clear mechanistic dissection from NF-κB pathway, replicated in multiple cell types\",\n      \"pmids\": [\"32433612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PYK2 (PTK2B) phosphorylates IRF5 and is required for endogenous IRF5 activation in macrophages. PYK2-deficient macrophages and pharmacological PYK2 inhibition (defactinib) reduce IRF5 activation and inflammatory gene expression, and defactinib reduces pro-inflammatory cytokines in human colon biopsies from ulcerative colitis patients.\",\n      \"method\": \"Kinase inhibitor library screen, PYK2-deficient macrophages, defactinib pharmacological inhibition, transcriptomic profiling, ex vivo human colon biopsies, mouse colitis model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic and pharmacological KO, transcriptomic similarity to IRF5 deficiency, ex vivo human tissue validation, in vivo mouse model\",\n      \"pmids\": [\"34795257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IRAK4 kinase activity controls IRF5 activation in the TLR-MyD88 pathway: IRAK4 inhibition abolishes IRF5 nuclear translocation and prevents IRF5 binding to inflammatory cytokine promoters. IRAK4 acts through TAK1→IKKβ→IRF5 phosphorylation, while NF-κB nuclear translocation is not blocked by IRAK4 inhibition.\",\n      \"method\": \"Selective IRAK4 inhibitor in human primary monocytes, ChIP (IRF5 at cytokine promoters), transcriptomics, signaling pathway analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition of IRAK4 with ChIP and transcriptomics readout, epistasis established by inhibitor cascade\",\n      \"pmids\": [\"28924041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IRF5 homodimer DNA-binding specificity was characterized by protein-binding microarrays; IRF5 homodimers do not bind the ISRE-variants present in IFN gene VREs, due to a critical specificity-determining residue. Mutational analysis reveals this residue inhibits IRF5 binding to IFN promoter ISRE-variants, distinguishing IRF5 from IRF3/IRF7 homodimers.\",\n      \"method\": \"Protein-binding microarrays (PBMs), site-directed mutagenesis, reporter gene assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted DNA-binding with PBMs, mutagenesis validation, multiple IRF comparators\",\n      \"pmids\": [\"29361124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF5 directly binds promoters of TGFβ1 (TGFB1) in adipose tissue macrophages and represses its transcription; genome-wide gene expression analysis in Irf5-deficient mice placed TGFβ1 as a direct IRF5 target, linking IRF5 to adipose tissue expansion and insulin sensitivity during obesity.\",\n      \"method\": \"Genome-wide gene expression analysis (ChIP/RNA-seq implied), Irf5−/− mouse model on high-fat diet, adipose tissue macrophage isolation\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genome-wide analysis with in vivo KO phenotype; direct ChIP for TGFB1 not explicitly stated in abstract, single lab\",\n      \"pmids\": [\"25939064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BCR-ABL kinase interacts with IRF5 in CML cells and induces tyrosine phosphorylation of IRF5, reducing its transcriptional activity. Imatinib treatment partially restores IRF5 transcriptional activity. A BCR-ABL consensus site mutant (IRF5Y104F) retains significant tyrosine phosphorylation, suggesting additional phosphorylation sites or downstream pathways.\",\n      \"method\": \"Co-immunoprecipitation (IRF5-BCR-ABL), phosphotyrosine immunoblot, imatinib treatment, site-directed mutagenesis, reporter assay, cell proliferation assay\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP and phosphorylation assay, mutagenesis, functional readout, single lab\",\n      \"pmids\": [\"24445143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF4 negatively regulates IRF5 at the transcriptional level by binding to the IRF5 promoter, repressing its reporter activity; IRF4 knockdown leads to high IRF5 expression and growth inhibition in EBV-transformed B cells, while knockdown of IRF5 rescues IRF4 knockdown-mediated growth inhibition.\",\n      \"method\": \"ChIP (IRF4 binding to IRF5 promoter), reporter assay, siRNA knockdown, ectopic overexpression, cell growth assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP binding, reporter assay, epistatic rescue experiment, single lab\",\n      \"pmids\": [\"21454650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IRF5 is not activated by viral infection directly (unlike IRF3), as assessed by phosphorylation, dimerization, nuclear translocation, CBP binding, and DNA recognition assays. However, ectopic expression of TBK1 or IKKε does activate IRF5. Constitutively active IRF5 promotes apoptosis that is inhibited by Bcl-xL but not dominant-negative FADD, placing IRF5 apoptosis in a FADD-independent pathway.\",\n      \"method\": \"Phosphorylation assay, nuclear translocation assay, dimerization assay, CBP binding assay, DNA binding assay, apoptosis assay with Bcl-xL and DN-FADD\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple assays for IRF5 activation, clear negative result for viral infection, pathway placement by dominant-negative approach\",\n      \"pmids\": [\"16751392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Higher basal IRF5 protein levels in female pDCs correlate with higher TLR7-mediated IFN-α production. Delivery of recombinant IRF5 into human primary pDCs directly increases TLR7-mediated IFN-α secretion. Genetic ablation of Esr1 (estrogen receptor 1) in hematopoietic cells or DC lineage reduces Irf5 mRNA in pDCs and IFN-α production, establishing ESR1-mediated transcriptional regulation of IRF5.\",\n      \"method\": \"Recombinant IRF5 protein delivery into primary human pDCs, conditional Esr1 KO mice, mRNA correlation analysis, IFN-α secretion assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein delivery experiment, conditional KO, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"26519527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF5 promotes differentiation of Ly6Chi monocytes into CD11c+ macrophages in the colon and controls production of antimicrobial and inflammatory mediators. IRF5 deficiency in mononuclear phagocytes ameliorates Helicobacter hepaticus-induced colitis, established via bone marrow chimera and single-cell RNA-sequencing.\",\n      \"method\": \"Irf5−/− mouse genetics, MNP-conditional IRF5 deletion, bone marrow chimera, single-cell RNA-sequencing, H. hepaticus colitis model\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-specific KO, scRNA-seq for mechanistic characterization, in vivo disease model, multiple orthogonal approaches\",\n      \"pmids\": [\"32444476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL4 costimulation synergistically activates TBK1 and IKKε, which are repurposed toward an inflammatory response via coupling with IRF5, leading to amplified inflammatory gene transcription. This CXCL4+TLR8 costimulation induces chromatin remodeling and de novo enhancer activation associated with inflammatory genes in human monocytes/macrophages.\",\n      \"method\": \"TBK1/IKKε/IRF5 signaling assays, ChIP-seq (chromatin remodeling), ATAC-seq (de novo enhancers), cytokine production assay in human monocytes/macrophages\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq and signaling biochemistry, human primary cells, multiple orthogonal methods\",\n      \"pmids\": [\"35701499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The autoimmune pleiotropic SNP rs4728142 modulates IRF5 alternative promoter usage: the rs4728142-containing region interacts with the IRF5 alternative promoter in an allele-specific manner via chromatin looping mediated by ZBTB3, promoting IRF5-short transcript expression at the risk allele and resulting in IRF5 overactivation and M1 macrophage polarization.\",\n      \"method\": \"Chromatin conformation capture (chromatin looping assay), allele-specific reporter assay, ZBTB3 functional analysis, IRF5 transcript quantification, macrophage polarization assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — chromatin looping established mechanistically with allele-specific readout, ZBTB3 identified as structural regulator, functional macrophage polarization outcome\",\n      \"pmids\": [\"36869052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF5 and IRF4 form a regulatory axis in microglia controlling pro- and anti-inflammatory responses after cerebral ischemia: down-regulation of IRF5 increases IRF4 expression and enhances M2 activation, while down-regulation of IRF4 increases IRF5 and M1 activation. The two IRFs mutually suppress each other in an oscillating pattern.\",\n      \"method\": \"siRNA knockdown, lentiviral overexpression, conditional KO (cKO), middle cerebral artery occlusion stroke model, flow cytometry, RT-PCR, multiplex cytokine analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with both siRNA and conditional KO, in vivo model, multiple readouts including in vitro and in vivo assays\",\n      \"pmids\": [\"31892541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRAK4 phosphorylates both IRF5 and IRF4 in microglia and forms a Myddosome complex with MyD88/IRF5/IRF4. IRAK4 inhibition reduces IRF5/IRF4 phosphorylation and nuclear translocation, quenches microglial pro-inflammatory responses, and increases neuronal viability after ischemia.\",\n      \"method\": \"Co-immunoprecipitation (Myddosome complex), Western blot for phospho-IRF5/IRF4, IRAK4 inhibitor (ND2158), SIM-A9 microglial cell line and primary microglia, OGD model\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP establishing complex, phosphorylation assays, pharmacological inhibition, single lab\",\n      \"pmids\": [\"33573200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF5 directly binds promoters of M1 macrophage-associated genes Ccl4, Ccl5, Tnf, and Il12b in myeloid cells during necrotizing enterocolitis, as shown by chromatin immunoprecipitation. Myeloid-specific Irf5 deficiency prevents experimental NEC by inhibiting M1 macrophage polarization and reducing intestinal epithelial apoptosis.\",\n      \"method\": \"ChIP (IRF5 binding to Ccl4, Ccl5, Tnf, Il12b promoters), myeloid-specific Irf5 KO, murine NEC model, immunohistochemistry\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP binding evidence, cell-specific KO with defined molecular and phenotypic readout\",\n      \"pmids\": [\"31086271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IRF5 drives TLR7-mediated IFN-α production in plasmacytoid dendritic cells and inflammatory cytokine production in myeloid cells downstream of TLR7 and possibly RIG-I, but independently of type I IFN production and virus replication. Human iPSC-derived DCs with biallelic IRF5 mutations show impaired virus-induced inflammatory cytokine production.\",\n      \"method\": \"Irf5−/− mouse in vivo IAV infection model, human iPSC with biallelic IRF5 mutations (iPSC-DCs and macrophages), CyTOF, cytokine assays\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO mouse and human iPSC genetic model, multiple cell types, CyTOF validation\",\n      \"pmids\": [\"32075938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"B cell receptor and TLR7 signaling synergize to promote IRF5 phosphorylation and increase IRF5 protein expression through independently regulated mechanisms. TLR7-dependent IRF5 nuclear translocation is reduced in B cells from IRF5-heterozygous mice. IRF5 drives IL-6 and TNF-α production in B cells, required for germinal center responses, and a critical threshold of IRF5 in B cells is required for lupus pathogenesis.\",\n      \"method\": \"Conditional B cell-specific Irf5 KO, IRF5 phosphorylation assay, nuclear translocation imaging, IL-6/TNF-α production assay, multiple murine lupus models\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO, multiple lupus models, mechanistic dissection of BCR and TLR7 signal convergence on IRF5\",\n      \"pmids\": [\"34197340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF5 in CD4+ T cells is required for the optimal assembly of the TCR-initiated signaling complex and downstream signaling, and binds to promoters of Th1- and Th17-associated transcription factors and cytokines at later timepoints. IRF5 also regulates chemokine receptor-initiated signaling and T cell migration. Irf5-deficient CD4+ T cells show reduced Th1/Th17 cytokines and increased Th2 cytokines in vivo.\",\n      \"method\": \"T cell-conditional IRF5 deletion, TCR signaling complex immunoprecipitation, ChIP (IRF5 binding to Th1/Th17 gene promoters), migration assay, colitis model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO, ChIP binding, signaling complex IP, migration and in vivo colitis assays\",\n      \"pmids\": [\"32610123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cell-penetrating peptides (CPPs) designed to disrupt IRF5 homodimerization directly bind to endogenous IRF5, are cell permeable, and inhibit IRF5-mediated IFN-α production in plasmacytoid dendritic cells. CPP activity corresponds to reduced nuclear phospho-Ser462 IRF5 without affecting overall pIRF5 levels, placing CPP action downstream of phosphorylation at the dimerization step.\",\n      \"method\": \"Biochemical binding assay, live-cell imaging, IRF5 homodimerization assay, IFN-α production assay, flow cytometry for nuclear pIRF5\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated, mechanistic placement downstream of phosphorylation, functional readout in primary cells, single lab\",\n      \"pmids\": [\"32440537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CLEC2D forms homodimers and heterodimers with TLR2; both dimeric forms mediate β-glucan-induced ubiquitination and degradation of MyD88, inhibiting IRF5 activation and IL-12 production. Clec2d-deficient female mice show increased IL-12 production and resistance to Candida albicans infection.\",\n      \"method\": \"Co-immunoprecipitation (CLEC2D-TLR2 dimerization), quantitative ligand binding assay, ubiquitination assay, Clec2d−/− mouse model, C. albicans infection model, cytokine assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP for dimerization, ubiquitination biochemistry, in vivo KO with mechanistic pathway dissection\",\n      \"pmids\": [\"37872182\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IRF5 is a signal-dependent transcription factor that, upon activation through the TLR-MyD88 pathway (requiring TRAF6, IRAK4, TAK1, and IKKβ-mediated phosphorylation at Ser445/Ser462), undergoes K63-linked ubiquitination, homodimerization, and nuclear translocation—a process negatively regulated by Lyn kinase, IKKα, KAP1/TRIM28, and CLEC2D; in the nucleus, IRF5 directly binds ISRE and composite PU.1:ISRE motifs at promoters of proinflammatory cytokines (IL-12, IL-23, TNF-α, IL-6) and represses IL-10, thereby driving M1 macrophage polarization, Th1/Th17 responses, B cell plasmablast differentiation, and death-receptor-mediated apoptosis, while its endolysosomal activation by TLR7/8/9 is specifically mediated by the adaptor TASL via SLC15A4.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IRF5 is a signal-dependent transcription factor that converts innate immune receptor engagement into proinflammatory gene programs, acting downstream of the TLR-MyD88 pathway through physical association with MyD88 and TRAF6 to drive nuclear translocation and induction of IL-6, IL-12, and TNF-\\u03b1, with Irf5-deficient mice failing to mount these responses and resisting endotoxin shock [#0]. Its activity is gated by a defined activation cascade: IRAK4 acts upstream through TAK1\\u2192IKK\\u03b2, which phosphorylates IRF5 at Ser445 and Ser462 to trigger dimerization and nuclear entry [#4, #5, #21], with PYK2 also required for endogenous IRF5 activation in macrophages [#20]; the protein carries a constitutive-activation domain, an autoinhibitory domain, dual nuclear localization signals, and a CRM1-dependent nuclear export signal that together govern its shuttling [#1, #2]. In the nucleus IRF5 binds ISRE and composite PU.1:ISRE motifs\\u2014cooperating physically with RelA/NF-\\u03baB p65\\u2014to activate IL-12/IL-23 family genes while repressing IL-10, thereby programming M1 macrophage polarization [#6, #7], and a specificity-determining residue excludes IRF5 homodimers from the IFN-promoter ISRE variants bound by IRF3/IRF7 [#22]. Beyond myeloid cells, IRF5 directly drives plasma cell commitment via the Prdm1/Blimp-1 promoter and B-cell class switching, supports Th1/Th17 differentiation and TCR signaling in CD4+ T cells, and mediates Fas/TRAIL death-receptor apoptosis upstream of caspase-8 [#9, #10, #11, #36]. Endolysosomal TLR7/8/9 signaling to IRF5 is routed through the adaptor TASL, which binds SLC15A4 and recruits IRF5 via a pLxIS motif [#19]. IRF5 output is restrained by multiple negative regulators, including IKK\\u03b1 (which blocks the K63-ubiquitination required for activity), Lyn kinase, KAP1/TRIM28, and the CLEC2D\\u2013TLR2 axis that degrades MyD88 [#3, #15, #14, #38]. Through these activities IRF5 is a central driver of inflammatory disease, with risk-associated promoter and looping variants increasing IRF5 expression and M1 polarization [#30].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established IRF5 as a DNA-damage-responsive transcription factor and defined the domain architecture and phosphosites needed for its transactivation, framing it as an inducible, phosphorylation-gated regulator before its innate-immune role was known.\",\n      \"evidence\": \"EMSA/reporter assays placing IRF5 as a direct p53 target, plus deletion and site-directed mutagenesis mapping activation/autoinhibitory domains and Ser477/Ser480\",\n      \"pmids\": [\"11973653\", \"12138184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The physiological upstream kinase for Ser477/480 was not identified\", \"Connection between p53-induced IRF5 and innate immune signaling not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved how IRF5 subcellular distribution is controlled, showing a CRM1-dependent nuclear export signal restrains it and that TBK1/IKK\\u03b5 phosphorylation, unlike for IRF3, does not activate it.\",\n      \"evidence\": \"Leptomycin B treatment, NES mutagenesis with subcellular imaging, and co-transfection kinase assays\",\n      \"pmids\": [\"15556946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the activating kinase\", \"Mechanism by which most IRF5 is held cytoplasmic in resting cells not fully defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified the core innate-immune function of IRF5 as a MyD88/TRAF6-coupled transcription factor essential for TLR-induced proinflammatory cytokine production in vivo.\",\n      \"evidence\": \"Irf5-/- mouse genetics, co-IP of IRF5 with MyD88/TRAF6, nuclear translocation and cytokine assays, endotoxin shock challenge\",\n      \"pmids\": [\"15665823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the activating phosphorylation event downstream of MyD88/TRAF6\", \"DNA-binding site preference at endogenous promoters not yet mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Clarified that IRF5 is not directly virus-activated like IRF3 and that constitutively active IRF5 drives FADD-independent apoptosis, distinguishing IRF5 from other IRFs functionally.\",\n      \"evidence\": \"Phosphorylation/dimerization/nuclear-translocation/DNA-binding assays and apoptosis assays with Bcl-xL and dominant-negative FADD\",\n      \"pmids\": [\"16751392\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous activating stimuli not defined in this study\", \"Apoptotic effector mechanism downstream of IRF5 not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Began dissecting the modifications gating IRF5 activity, showing IKK\\u03b1 phosphorylation induces dimerization but inhibits activity by blocking the K63-ubiquitination IRF5 requires.\",\n      \"evidence\": \"Co-IP, in vitro kinase and ubiquitination assays, reporter assays\",\n      \"pmids\": [\"19786094\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating K63 ubiquitination not identified\", \"Limited independent replication of the IKK\\u03b1 inhibitory role\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed IRF5 transactivation is coupled to chromatin-modifying complexes, with HDAC- and HAT-containing assemblies dynamically converting an IRF5 silencing complex to an activating one at target promoters.\",\n      \"evidence\": \"Co-IP with HDAC1/Sin3a/HATs, TSA inhibitor treatment, reporter assays, domain mapping\",\n      \"pmids\": [\"20935208\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter-specific recruitment of each complex not fully defined\", \"Single-lab data without genome-wide validation\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined IRF5 as the molecular driver of M1 macrophage polarization by directly activating IL-12/IL-23 family genes and repressing IL-10.\",\n      \"evidence\": \"ChIP at target promoters, IRF5 overexpression, expression profiling, polarization assays\",\n      \"pmids\": [\"21240265\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of IL-10 repression not detailed\", \"Cofactor requirements at activating versus repressing targets not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended IRF5's transcriptional roles into B-cell biology (class switching via repressing IRF8-driven Ikaros) and identified KAP1/TRIM28 and SETDB1 as corepressors of IRF5.\",\n      \"evidence\": \"Irf5-/- mice with SCID reconstitution and ChIP at ikzf1; AP-MS and functional knockdown for KAP1/TRIM28\",\n      \"pmids\": [\"22535200\", \"22995936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"KAP1/SETDB1-mediated repression mechanism at endogenous IRF5 targets not fully resolved\", \"How IRF5 switches between activating and IRF8-antagonizing modes unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified the principal activating kinase axis as IKK\\u03b2 phosphorylating IRF5 at Ser445 and Ser462 downstream of TAK1, the events required for dimerization, nuclear translocation, and cytokine/IFN\\u03b2 output.\",\n      \"evidence\": \"In vitro kinase assays with recombinant IKK\\u03b2, MS phosphosite mapping, phospho-specific antibodies, Ser-to-Ala mutants, siRNA and pharmacological inhibition of IKK\\u03b2/TAK1\",\n      \"pmids\": [\"25326420\", \"25326418\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase for the required K63 ubiquitination still unidentified\", \"Whether both serines are phosphorylated simultaneously or sequentially not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped IRF5's genomic engagement and a key DNA-binding cofactor, showing it uses composite PU.1:ISRE motifs and physically partners with RelA to control a subset of inflammatory genes.\",\n      \"evidence\": \"Genome-wide ChIP-seq, protein:DNA microarrays, reciprocal co-IP, transcriptomics in IRF5- and RelA-deficient macrophages\",\n      \"pmids\": [\"25159141\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of the RelA dependency across cell types not established\", \"Determinants selecting composite versus ISRE-only sites not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Broadened IRF5's direct-target repertoire to neuronal/glial contexts, defining an IRF8\\u2192IRF5\\u2192P2X4R axis driving neuropathic pain.\",\n      \"evidence\": \"ChIP at the P2rx4 promoter, Irf5-/- mice, behavioral pain assays, IRF8/IRF5 expression analysis\",\n      \"pmids\": [\"24818655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal triggering microglial IRF5 activation in vivo not pinpointed\", \"Whether IRF8 regulates IRF5 directly at the transcriptional level not shown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Placed IRF5 within the cytosolic RNA-sensing pathway, showing IRF3/IRF5/IRF7 collectively are required for MAVS-dependent type I IFN/ISG responses in myeloid DCs.\",\n      \"evidence\": \"Irf3xIrf5xIrf7 triple-KO mouse genetics, microarray transcriptomics, viral infection and pathogenesis assays\",\n      \"pmids\": [\"23300459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The unique non-redundant IRF5 contribution versus IRF3/IRF7 not isolated\", \"Direct MAVS-to-IRF5 biochemical link not demonstrated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established additional negative-target and disease links, with IRF5 directly repressing TGF\\u03b21 in adipose macrophages affecting metabolic disease, and ESR1-mediated transcriptional control of IRF5 underlying sex-biased IFN-\\u03b1 responses.\",\n      \"evidence\": \"Genome-wide expression analysis in Irf5-/- mice on high-fat diet; recombinant IRF5 delivery into human pDCs plus conditional Esr1 KO\",\n      \"pmids\": [\"25939064\", \"26519527\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ChIP at TGFB1 not explicitly demonstrated\", \"Mechanism of ESR1-driven IRF5 transcription not detailed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified key negative regulators and an additional receptor input, showing Lyn kinase suppresses IRF5 K63-ubiquitination/phosphorylation kinase-independently, and that NOD2 engages IRF5 with RIP2/IRAK1/TRAF6 to drive Akt2-dependent glycolysis and M1 polarization.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, kinase-dead Lyn mutant, Lyn-/-Irf5+/- compound mice; co-IP of IRF5 signaling complex with Akt2 assays and human macrophage genotyping\",\n      \"pmids\": [\"27521268\", \"27545875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Lyn physically blocks ubiquitination mechanistically not resolved\", \"Direct versus indirect IRF5\\u2013Akt2 connection not fully defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed IRAK4 kinase activity at the apex of the MyD88\\u2192TAK1\\u2192IKK\\u03b2\\u2192IRF5 cascade, separable from NF-\\u03baB, validating IRF5 activation as a targetable inflammatory node.\",\n      \"evidence\": \"Selective IRAK4 inhibition in human monocytes with ChIP of IRF5 at cytokine promoters and transcriptomics\",\n      \"pmids\": [\"28924041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IRAK4 phosphorylates IRF5 directly or only via the cascade not distinguished here\", \"Selectivity of downstream gene effects not exhaustively mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Explained the molecular basis for IRF5's distinct promoter selectivity, identifying a specificity-determining residue that excludes IRF5 homodimers from the IFN-gene ISRE variants bound by IRF3/IRF7.\",\n      \"evidence\": \"Protein-binding microarrays of IRF5 homodimers, site-directed mutagenesis, reporter assays\",\n      \"pmids\": [\"29361124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequences of the specificity residue not tested\", \"How heterodimerization or cofactors alter this specificity not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated context-specific direct targets and a reciprocal IRF5/IRF4 polarization switch, with IRF5 binding M1 chemokine/cytokine promoters in intestinal disease and mutually antagonizing IRF4 in microglia.\",\n      \"evidence\": \"ChIP at Ccl4/Ccl5/Tnf/Il12b with myeloid-specific Irf5 KO NEC model; siRNA/overexpression/cKO with stroke model for the IRF5/IRF4 axis\",\n      \"pmids\": [\"31086271\", \"31892541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of mutual IRF5/IRF4 suppression not fully defined\", \"Upstream cues setting the IRF5:IRF4 balance unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified TASL/SLC15A4 as the missing adaptor linking endolysosomal TLR7/8/9 specifically to IRF5, and extended IRF5's roles into monocyte-to-macrophage differentiation, CD4+ T-cell TCR signaling/Th1-Th17 programs, and human antiviral immunity.\",\n      \"evidence\": \"TASL/SLC15A4 deletion and pLxIS-motif mutagenesis in human immune cells; Irf5-/- and conditional KO mice with scRNA-seq, colitis and infection models, human iPSC-DCs\",\n      \"pmids\": [\"32433612\", \"32444476\", \"32610123\", \"32075938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TASL pLxIS recruitment of IRF5 not resolved\", \"How a single factor coordinates such distinct cell-type programs unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified additional activating kinases and signal-convergence mechanisms, showing PYK2 is required for endogenous IRF5 activation, IRAK4 forms a MyD88/IRF5/IRF4 Myddosome in microglia, and BCR plus TLR7 synergize to raise IRF5 phosphorylation/expression to a lupus-relevant threshold in B cells.\",\n      \"evidence\": \"Kinase inhibitor screen and PYK2-deficient macrophages with defactinib; Myddosome co-IP and IRAK4 inhibition in microglia; B-cell-conditional Irf5 KO across lupus models\",\n      \"pmids\": [\"34795257\", \"33573200\", \"34197340\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PYK2 phosphosite on IRF5 not mapped\", \"How BCR and TLR7 inputs are integrated quantitatively to set the IRF5 threshold not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established IRF5 dimerization as a druggable step, with cell-penetrating peptides that bind IRF5 and block homodimerization acting downstream of phosphorylation to reduce nuclear pSer462-IRF5 and IFN-\\u03b1.\",\n      \"evidence\": \"Biochemical binding, live-cell imaging, dimerization and IFN-\\u03b1 assays, flow cytometry of nuclear pIRF5 in pDCs\",\n      \"pmids\": [\"32440537\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo efficacy and selectivity not established\", \"Structural detail of the disrupted dimer interface not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Connected human autoimmune-risk genetics to IRF5 dosage and showed inhibitory checkpoints, with the rs4728142/ZBTB3 looping mechanism raising IRF5-short transcript and M1 polarization, and CLEC2D-TLR2 degrading MyD88 to limit IRF5 activation.\",\n      \"evidence\": \"Chromatin conformation capture with allele-specific reporters and ZBTB3 analysis; co-IP, ubiquitination assays and Clec2d-/- mice with Candida infection\",\n      \"pmids\": [\"36869052\", \"37872182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional difference between IRF5-short and full-length isoforms mechanistically incomplete\", \"Whether CLEC2D-driven MyD88 degradation generalizes beyond \\u03b2-glucan/TLR2 contexts unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The E3 ligase mediating the K63-linked ubiquitination required for IRF5 activation, and a unifying structural model explaining how phosphorylation, ubiquitination, dimerization, and cofactor selection (PU.1, RelA, IRF4/IRF8, KAP1) are integrated across cell types, remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No K63 E3 ligase identified despite ubiquitination being mechanistically central\", \"No integrated structural model of the activated IRF5 dimer with cofactors\", \"Determinants directing IRF5 to activating versus repressive target genes unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 7, 9, 10, 33, 36]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [6, 7, 9, 22, 33]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 5, 21]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 6, 7, 19, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 5, 16, 19, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 7, 9, 10, 33]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [11, 26]}\n    ],\n    \"complexes\": [\"Myddosome (MyD88/IRF5/IRF4)\", \"TASL-SLC15A4 complex\"],\n    \"partners\": [\"MYD88\", \"TRAF6\", \"IKBKB\", \"RELA\", \"TASL\", \"LYN\", \"TRIM28\", \"IRAK4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}